SITC connectED Clinician Portal

Advances in Cancer Immunotherapy™: A Focus on Immune Checkpoint Inhibitors Expand Advances in Cancer Immunotherapy™: A Focus on Immune Checkpoint Inhibitors for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Immune Checkpoint Inhibitors

Updates on the Immunotherapy Treatment Paradigm for Mesothelioma Expand Updates on the Immunotherapy Treatment Paradigm for Mesothelioma for more information

Collapse Updates on the Immunotherapy Treatment Paradigm for Mesothelioma

Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations Expand Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations for more information

Collapse Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations

Evaluating the Role of Immunotherapy in Urothelial Carcinoma: How Do We Make the Right Choices? Expand Evaluating the Role of Immunotherapy in Urothelial Carcinoma: How Do We Make the Right Choices? for more information

Collapse Evaluating the Role of Immunotherapy in Urothelial Carcinoma: How Do We Make the Right Choices?

Immunotherapy in Early-Stage NSCLC Expand Immunotherapy in Early-Stage NSCLC for more information

Collapse Immunotherapy in Early-Stage NSCLC

Advances in Cancer Immunotherapy™: A Focus on Skin Cancers Expand Advances in Cancer Immunotherapy™: A Focus on Skin Cancers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Skin Cancers

Optimizing the Management of Squamous Cell Carcinoma of the Head and Neck With Immunotherapeutic Strategies Expand Optimizing the Management of Squamous Cell Carcinoma of the Head and Neck With Immunotherapeutic Strategies for more information

Collapse Optimizing the Management of Squamous Cell Carcinoma of the Head and Neck With Immunotherapeutic Strategies

Advances in Cancer Immunotherapy™: A Focus on Intratumoral Therapies, Vaccines, and Cytokines Expand Advances in Cancer Immunotherapy™: A Focus on Intratumoral Therapies, Vaccines, and Cytokines for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Intratumoral Therapies, Vaccines, and Cytokines

Head and Neck Squamous Cell Carcinoma CPG Mini Module - Risks and Benefits of Immunotherapy Combination Therapies to Treat Oligometastatic Disease Expand Head and Neck Squamous Cell Carcinoma CPG Mini Module - Risks and Benefits of Immunotherapy Combination Therapies to Treat Oligometastatic Disease for more information

Expand Head and Neck Squamous Cell Carcinoma CPG Mini Module - Risks and Benefits of Immunotherapy Combination Therapies to Treat Oligometastatic Disease for more information

Collapse Head and Neck Squamous Cell Carcinoma CPG Mini Module - Risks and Benefits of Immunotherapy Combination Therapies to Treat Oligometastatic Disease

Head and Neck Squamous Cell Carcinoma CPG Mini Module - Selecting Appropriate Treatment Strategies for Recurrent/Metastatic HNSCC Expand Head and Neck Squamous Cell Carcinoma CPG Mini Module - Selecting Appropriate Treatment Strategies for Recurrent/Metastatic HNSCC for more information

Expand Head and Neck Squamous Cell Carcinoma CPG Mini Module - Selecting Appropriate Treatment Strategies for Recurrent/Metastatic HNSCC for more information

Collapse Head and Neck Squamous Cell Carcinoma CPG Mini Module - Selecting Appropriate Treatment Strategies for Recurrent/Metastatic HNSCC

Advances in Cancer Immunotherapy™: A Focus on Head and Neck Cancers Expand Advances in Cancer Immunotherapy™: A Focus on Head and Neck Cancers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Head and Neck Cancers

Advances in Cancer Immunotherapy™: A Focus on Cellular Therapies and T Cell Engagers Expand Advances in Cancer Immunotherapy™: A Focus on Cellular Therapies and T Cell Engagers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Cellular Therapies and T Cell Engagers

Advances in Cancer Immunotherapy™: A Focus on Gynecologic Cancers Expand Advances in Cancer Immunotherapy™: A Focus on Gynecologic Cancers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Gynecologic Cancers

Urothelial Cancer CPG Mini Module - Immune Irritability and Management of Immune-Related Adverse Effects Expand Urothelial Cancer CPG Mini Module - Immune Irritability and Management of Immune-Related Adverse Effects for more information

Collapse Urothelial Cancer CPG Mini Module - Immune Irritability and Management of Immune-Related Adverse Effects

Advances in Cancer Immunotherapy™: A Focus on MSI-High and TMB-High Cancers Expand Advances in Cancer Immunotherapy™: A Focus on MSI-High and TMB-High Cancers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on MSI-High and TMB-High Cancers

Advances in Cancer Immunotherapy™: A Focus on Gastrointestinal Cancers Expand Advances in Cancer Immunotherapy™: A Focus on Gastrointestinal Cancers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Gastrointestinal Cancers

Advances in Cancer Immunotherapy™: A Focus on Monoclonal Antibodies and Antibody-drug Conjugates Expand Advances in Cancer Immunotherapy™: A Focus on Monoclonal Antibodies and Antibody-drug Conjugates for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Monoclonal Antibodies and Antibody-drug Conjugates

Advances in Cancer Immunotherapy™: A Focus on Lung Cancers Expand Advances in Cancer Immunotherapy™: A Focus on Lung Cancers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Lung Cancers

Advances in Cancer Immunotherapy™: A Focus on Hematologic Malignancies Expand Advances in Cancer Immunotherapy™: A Focus on Hematologic Malignancies for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Hematologic Malignancies

Advances in Cancer Immunotherapy™: A Focus on Breast Cancers Expand Advances in Cancer Immunotherapy™: A Focus on Breast Cancers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Breast Cancers

Advances in Cancer Immunotherapy™: A Focus on Toxicity Management Expand Advances in Cancer Immunotherapy™: A Focus on Toxicity Management for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Toxicity Management

Advances in Cancer Immunotherapy™: A Focus on Biomarkers Expand Advances in Cancer Immunotherapy™: A Focus on Biomarkers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Biomarkers

Advances in Cancer Immunotherapy™: A Focus on Genitourinary Cancers Expand Advances in Cancer Immunotherapy™: A Focus on Genitourinary Cancers for more information

Collapse Advances in Cancer Immunotherapy™: A Focus on Genitourinary Cancers

Lung Cancer and Mesothelioma CPG Mini Module – Key Principles of Immune Related Adverse Events (irAEs) Expand Lung Cancer and Mesothelioma CPG Mini Module – Key Principles of Immune Related Adverse Events (irAEs) for more information

Collapse Lung Cancer and Mesothelioma CPG Mini Module – Key Principles of Immune Related Adverse Events (irAEs)

Lung Cancer and Mesothelioma CPG Mini Module – Managing Stage III Non-Small Cell Lung Cancer (NSCLC) Expand Lung Cancer and Mesothelioma CPG Mini Module – Managing Stage III Non-Small Cell Lung Cancer (NSCLC) for more information

Collapse Lung Cancer and Mesothelioma CPG Mini Module – Managing Stage III Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer and Mesothelioma CPG Mini Module – Immunotherapy for Lung Cancer in Challenging Populations Expand Lung Cancer and Mesothelioma CPG Mini Module – Immunotherapy for Lung Cancer in Challenging Populations for more information

Collapse Lung Cancer and Mesothelioma CPG Mini Module – Immunotherapy for Lung Cancer in Challenging Populations

Non-Melanoma Skin Cancers CPG Mini Module – Immunotherapy in Challenging Populations in Non-Melanoma Skin Cancer Expand Non-Melanoma Skin Cancers CPG Mini Module – Immunotherapy in Challenging Populations in Non-Melanoma Skin Cancer for more information

Collapse Non-Melanoma Skin Cancers CPG Mini Module – Immunotherapy in Challenging Populations in Non-Melanoma Skin Cancer

Non-Melanoma Skin Cancers CPG Mini Module – Overcoming Immune Evasion in Merkel Cell Carcinoma Expand Non-Melanoma Skin Cancers CPG Mini Module – Overcoming Immune Evasion in Merkel Cell Carcinoma for more information

Collapse Non-Melanoma Skin Cancers CPG Mini Module – Overcoming Immune Evasion in Merkel Cell Carcinoma

Non-Melanoma Skin Cancers CPG Mini Module – New Developments in Neoadjuvant Therapy for Non-Melanoma Skin Cancers Expand Non-Melanoma Skin Cancers CPG Mini Module – New Developments in Neoadjuvant Therapy for Non-Melanoma Skin Cancers for more information

Collapse Non-Melanoma Skin Cancers CPG Mini Module – New Developments in Neoadjuvant Therapy for Non-Melanoma Skin Cancers

Hepatocellular Carcinoma SITC CPG Mini Module - Immunotherapy for HCC with Child-Pugh B Cirrhosis Expand Hepatocellular Carcinoma SITC CPG Mini Module - Immunotherapy for HCC with Child-Pugh B Cirrhosis for more information

Collapse Hepatocellular Carcinoma SITC CPG Mini Module - Immunotherapy for HCC with Child-Pugh B Cirrhosis

Hepatocellular Carcinoma SITC CPG Mini Module - Immuno-Oncology Combination Therapy (IO-IO Therapy) in Second-Line Treatment of HCC Expand Hepatocellular Carcinoma SITC CPG Mini Module - Immuno-Oncology Combination Therapy (IO-IO Therapy) in Second-Line Treatment of HCC for more information

Expand Hepatocellular Carcinoma SITC CPG Mini Module - Immuno-Oncology Combination Therapy (IO-IO Therapy) in Second-Line Treatment of HCC for more information

Collapse Hepatocellular Carcinoma SITC CPG Mini Module - Immuno-Oncology Combination Therapy (IO-IO Therapy) in Second-Line Treatment of HCC

Hepatocellular Carcinoma SITC CPG Mini Module - Front-Line Management for Advanced Hepatocellular Carcinoma Expand Hepatocellular Carcinoma SITC CPG Mini Module - Front-Line Management for Advanced Hepatocellular Carcinoma for more information

Collapse Hepatocellular Carcinoma SITC CPG Mini Module - Front-Line Management for Advanced Hepatocellular Carcinoma

Breast Cancer CPG Mini Module - Toxicities and Adverse Events Expand Breast Cancer CPG Mini Module - Toxicities and Adverse Events for more information

Collapse Breast Cancer CPG Mini Module - Toxicities and Adverse Events

Breast Cancer CPG Mini Module - First-Line Treatment of Metastatic TNBC Expand Breast Cancer CPG Mini Module - First-Line Treatment of Metastatic TNBC for more information

Collapse Breast Cancer CPG Mini Module - First-Line Treatment of Metastatic TNBC

Breast Cancer CPG Mini-Module - Neoadjuvant and Adjuvant Treatment Expand Breast Cancer CPG Mini-Module - Neoadjuvant and Adjuvant Treatment for more information

Collapse Breast Cancer CPG Mini-Module - Neoadjuvant and Adjuvant Treatment

Urothelial Cancer CPG Mini Module - Management of High-Risk Non-Muscle Invasive Bladder Cancer Expand Urothelial Cancer CPG Mini Module - Management of High-Risk Non-Muscle Invasive Bladder Cancer for more information

Collapse Urothelial Cancer CPG Mini Module - Management of High-Risk Non-Muscle Invasive Bladder Cancer

Urothelial Cancer CPG Mini Module - Treatment of Unresectable Bladder Cancer Expand Urothelial Cancer CPG Mini Module - Treatment of Unresectable Bladder Cancer for more information

Collapse Urothelial Cancer CPG Mini Module - Treatment of Unresectable Bladder Cancer

ICI-irAEs CPG Mini Module - Vaccines and Chronic irAEs Expand ICI-irAEs CPG Mini Module - Vaccines and Chronic irAEs for more information

Collapse ICI-irAEs CPG Mini Module - Vaccines and Chronic irAEs

ICI-irAEs CPG Mini Module - Autoimmune Disease Expand ICI-irAEs CPG Mini Module - Autoimmune Disease for more information

Collapse ICI-irAEs CPG Mini Module - Autoimmune Disease

ICI-irAEs CPG Mini Module - Special Patient Populations Expand ICI-irAEs CPG Mini Module - Special Patient Populations for more information

Collapse ICI-irAEs CPG Mini Module - Special Patient Populations

Lymphoma CPG Mini Module - Bispecifics Expand Lymphoma CPG Mini Module - Bispecifics for more information

Collapse Lymphoma CPG Mini Module - Bispecifics

Lymphoma CPG Mini Module - CAR T Expand Lymphoma CPG Mini Module - CAR T for more information

Collapse Lymphoma CPG Mini Module - CAR T

Lymphoma CPG Mini Module - Integration with Transplant Expand Lymphoma CPG Mini Module - Integration with Transplant for more information

Collapse Lymphoma CPG Mini Module - Integration with Transplant

IEC-rAEs CPG Mini Module - Product-specific Toxicity Expand IEC-rAEs CPG Mini Module - Product-specific Toxicity for more information

Collapse IEC-rAEs CPG Mini Module - Product-specific Toxicity

IEC-rAEs CPG Mini Module - ICANS Expand IEC-rAEs CPG Mini Module - ICANS for more information

Collapse IEC-rAEs CPG Mini Module - ICANS

IEC-rAEs CPG Mini Module - CRS and HLH Expand IEC-rAEs CPG Mini Module - CRS and HLH for more information

Collapse IEC-rAEs CPG Mini Module - CRS and HLH

Acute Leukemia CPG Mini Module - CAR T Cell Therapy for Acute Lymphocytic Leukemia in Adults Expand Acute Leukemia CPG Mini Module - CAR T Cell Therapy for Acute Lymphocytic Leukemia in Adults for more information

Collapse Acute Leukemia CPG Mini Module - CAR T Cell Therapy for Acute Lymphocytic Leukemia in Adults

Acute Leukemia CPG Mini Module - Antibody-Drug Conjugates for Treatment of Acute Leukemia Expand Acute Leukemia CPG Mini Module - Antibody-Drug Conjugates for Treatment of Acute Leukemia for more information

Collapse Acute Leukemia CPG Mini Module - Antibody-Drug Conjugates for Treatment of Acute Leukemia

Acute Leukemia CPG Mini Module - Sequencing Therapies for Acute Leukemia Expand Acute Leukemia CPG Mini Module - Sequencing Therapies for Acute Leukemia for more information

Collapse Acute Leukemia CPG Mini Module - Sequencing Therapies for Acute Leukemia

Renal Cell Carcinoma CPG Mini Module - Planning Immunotherapy Regiments for Challenging Patient Populations Expand Renal Cell Carcinoma CPG Mini Module - Planning Immunotherapy Regiments for Challenging Patient Populations for more information

Collapse Renal Cell Carcinoma CPG Mini Module - Planning Immunotherapy Regiments for Challenging Patient Populations

Renal Cell Carcinoma CPG Mini Module - Management of Toxicities Expand Renal Cell Carcinoma CPG Mini Module - Management of Toxicities for more information

Collapse Renal Cell Carcinoma CPG Mini Module - Management of Toxicities

Renal Cell Carcinoma CPG Mini Module - Management of Clear Cell Renal Cell Carcinoma with Large Metastatic Burden Expand Renal Cell Carcinoma CPG Mini Module - Management of Clear Cell Renal Cell Carcinoma with Large Metastatic Burden for more information

Collapse Renal Cell Carcinoma CPG Mini Module - Management of Clear Cell Renal Cell Carcinoma with Large Metastatic Burden

Head and Neck Squamous Cell Carcinoma CPG Mini Module - Identifying Pseudoprogression and Managing Disease Unresponsive to Immunotherapy Expand Head and Neck Squamous Cell Carcinoma CPG Mini Module - Identifying Pseudoprogression and Managing Disease Unresponsive to Immunotherapy for more information

Expand Head and Neck Squamous Cell Carcinoma CPG Mini Module - Identifying Pseudoprogression and Managing Disease Unresponsive to Immunotherapy for more information

Collapse Head and Neck Squamous Cell Carcinoma CPG Mini Module - Identifying Pseudoprogression and Managing Disease Unresponsive to Immunotherapy

Multiple Myeloma CPG Mini Module - CAR T and Bispecifics Expand Multiple Myeloma CPG Mini Module - CAR T and Bispecifics for more information

Collapse Multiple Myeloma CPG Mini Module - CAR T and Bispecifics

Multiple Myeloma CPG Mini Module - Antibody-Drug Conjugates Expand Multiple Myeloma CPG Mini Module - Antibody-Drug Conjugates for more information

Collapse Multiple Myeloma CPG Mini Module - Antibody-Drug Conjugates

Multiple Myeloma CPG Mini Module - Monoclonal Antibodies Expand Multiple Myeloma CPG Mini Module - Monoclonal Antibodies for more information

Collapse Multiple Myeloma CPG Mini Module - Monoclonal Antibodies

Immunotherapy for the Treatment of Gastrointestinal Cancers Expand Immunotherapy for the Treatment of Gastrointestinal Cancers for more information

Collapse Immunotherapy for the Treatment of Gastrointestinal Cancers

Toxicity Management Expand Toxicity Management for more information

Basic Principles of Cancer Immunotherapy Expand Basic Principles of Cancer Immunotherapy for more information

Collapse Basic Principles of Cancer Immunotherapy

Immunotherapy for the Treatment of Skin Cancers Expand Immunotherapy for the Treatment of Skin Cancers for more information

Collapse Immunotherapy for the Treatment of Skin Cancers

Certificate in Cancer Immunotherapy Module 1: Basic Immunology Concepts Expand Certificate in Cancer Immunotherapy Module 1: Basic Immunology Concepts for more information

2021 Clinician Courses (41 Courses)

Collapse Certificate in Cancer Immunotherapy Module 1: Basic Immunology Concepts

Lymphoma CPG Mini Module - Integration with Transplant Expand Lymphoma CPG Mini Module - Integration with Transplant for more information

Lymphoma CPG Mini Module - CAR T Expand Lymphoma CPG Mini Module - CAR T for more information

Lymphoma CPG Mini Module - Bispecifics Expand Lymphoma CPG Mini Module - Bispecifics for more information

ICI-irAEs CPG Mini Module - Special Patient Populations Expand ICI-irAEs CPG Mini Module - Special Patient Populations for more information

ICI-irAEs CPG Mini Module - Autoimmune Disease Expand ICI-irAEs CPG Mini Module - Autoimmune Disease for more information

ICI-irAEs CPG Mini Module - Vaccines and Chronic irAEs Expand ICI-irAEs CPG Mini Module - Vaccines and Chronic irAEs for more information

IEC-rAEs CPG Mini Module - CRS and HLH Expand IEC-rAEs CPG Mini Module - CRS and HLH for more information

IEC-rAEs CPG Mini Module - Product-specific Toxicity Expand IEC-rAEs CPG Mini Module - Product-specific Toxicity for more information

Breast Cancer CPG Mini-Module - Neoadjuvant and Adjuvant Treatment Expand Breast Cancer CPG Mini-Module - Neoadjuvant and Adjuvant Treatment for more information

Breast Cancer CPG Mini Module - First-Line Treatment of Metastatic TNBC Expand Breast Cancer CPG Mini Module - First-Line Treatment of Metastatic TNBC for more information

Breast Cancer CPG Mini Module - Toxicities and Adverse Events Expand Breast Cancer CPG Mini Module - Toxicities and Adverse Events for more information

Acute Leukemia CPG Mini Module - Sequencing Therapies for Acute Leukemia Expand Acute Leukemia CPG Mini Module - Sequencing Therapies for Acute Leukemia for more information

Multiple Myeloma CPG Mini Module - Monoclonal Antibodies Expand Multiple Myeloma CPG Mini Module - Monoclonal Antibodies for more information

Multiple Myeloma CPG Mini Module - Antibody-Drug Conjugates Expand Multiple Myeloma CPG Mini Module - Antibody-Drug Conjugates for more information

Multiple Myeloma CPG Mini Module - CAR T and Bispecifics Expand Multiple Myeloma CPG Mini Module - CAR T and Bispecifics for more information

Advances in Cancer Immunotherapy ™ Webinar: Clinical Updates from ESMO Immuno-Oncology Congress 2020: Claim Credit Expand Advances in Cancer Immunotherapy ™ Webinar: Clinical Updates from ESMO Immuno-Oncology Congress 2020: Claim Credit for more information

Collapse Advances in Cancer Immunotherapy ™ Webinar: Clinical Updates from ESMO Immuno-Oncology Congress 2020: Claim Credit

Basic Principles of Cancer Immunotherapy Expand Basic Principles of Cancer Immunotherapy for more information

Toxicity Management Expand Toxicity Management for more information

Immunotherapy for the Treatment of Genitourinary Malignancies Expand Immunotherapy for the Treatment of Genitourinary Malignancies for more information

Collapse Immunotherapy for the Treatment of Genitourinary Malignancies

Immunotherapy for the Treatment of Gastrointestinal Cancers Expand Immunotherapy for the Treatment of Gastrointestinal Cancers for more information

Immunotherapy for the Treatment of the Head and Neck Cancer Expand Immunotherapy for the Treatment of the Head and Neck Cancer for more information

Collapse Immunotherapy for the Treatment of the Head and Neck Cancer

Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutation Burden - High Cancers Expand Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutation Burden - High Cancers for more information

Collapse Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutation Burden - High Cancers

Immunotherapy for the Treatment of Hematologic Malignancies Expand Immunotherapy for the Treatment of Hematologic Malignancies for more information

Collapse Immunotherapy for the Treatment of Hematologic Malignancies

What's Next in Cancer Immunotherapy? Expand What

Immunotherapy for the Treatment of Lung Cancer Expand Immunotherapy for the Treatment of Lung Cancer for more information

Collapse Immunotherapy for the Treatment of Lung Cancer

Immunotherapy for the Treatment of Breast and Gynecologic Cancers Expand Immunotherapy for the Treatment of Breast and Gynecologic Cancers for more information

Collapse Immunotherapy for the Treatment of Breast and Gynecologic Cancers

Navigating the Management of Triple-Negative Breast Cancer: Immunotherapy Considerations Expand Navigating the Management of Triple-Negative Breast Cancer: Immunotherapy Considerations for more information

Collapse Navigating the Management of Triple-Negative Breast Cancer: Immunotherapy Considerations

Obtaining the Pieces to the Puzzle: Real-World Considerations in the First-Line Management of mNSCLC Expand Obtaining the Pieces to the Puzzle: Real-World Considerations in the First-Line Management of mNSCLC for more information

Collapse Obtaining the Pieces to the Puzzle: Real-World Considerations in the First-Line Management of mNSCLC

Everything You Need to Know About ICIs in Gynecologic Cancers Expand Everything You Need to Know About ICIs in Gynecologic Cancers for more information

Collapse Everything You Need to Know About ICIs in Gynecologic Cancers

Management of Bladder Cancer: Case Challenges Expand Management of Bladder Cancer: Case Challenges for more information

Collapse Management of Bladder Cancer: Case Challenges

Expanding the Role of Immunotherapy in the Treatment of Gastric/GEJ Cancers Expand Expanding the Role of Immunotherapy in the Treatment of Gastric/GEJ Cancers for more information

Collapse Expanding the Role of Immunotherapy in the Treatment of Gastric/GEJ Cancers

Advances in Cancer Immunotherapy^TM Webinar: Clinical Updates from SITC 2020: Claim Credit Expand Advances in Cancer Immunotherapy<sup>TM</sup> Webinar: Clinical Updates from SITC 2020: Claim Credit for more information

Collapse Advances in Cancer Immunotherapy<sup>TM</sup> Webinar: Clinical Updates from SITC 2020: Claim Credit

Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers Expand Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers for more information

Collapse Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers

Treatment Algorithms in Melanoma: Evaluating Where We Are and Where We Are Headed Expand Treatment Algorithms in Melanoma: Evaluating Where We Are and Where We Are Headed for more information

Collapse Treatment Algorithms in Melanoma: Evaluating Where We Are and Where We Are Headed

Special Populations and Immune Checkpoint Inhibitors: Are They Safe? Expand Special Populations and Immune Checkpoint Inhibitors: Are They Safe? for more information

Collapse Special Populations and Immune Checkpoint Inhibitors: Are They Safe?

Practical Barriers in Cancer Immunotherapy Treatment Expand Practical Barriers in Cancer Immunotherapy Treatment for more information

Collapse Practical Barriers in Cancer Immunotherapy Treatment

Steps and Considerations to Optimizing Management of Recurrent/Metastatic Head and Neck Cancer Expand Steps and Considerations to Optimizing Management of Recurrent/Metastatic Head and Neck Cancer for more information

Collapse Steps and Considerations to Optimizing Management of Recurrent/Metastatic Head and Neck Cancer

Updates on Immune Modulators in Lung Cancer: Have We Met the Need? Expand Updates on Immune Modulators in Lung Cancer: Have We Met the Need? for more information

Collapse Updates on Immune Modulators in Lung Cancer: Have We Met the Need?

Shifting the Balance Between the Immune System and Cancer: Moving Beyond the PD-1/PD-L1 Axis Expand Shifting the Balance Between the Immune System and Cancer: Moving Beyond the PD-1/PD-L1 Axis for more information

2020 Clinician Courses (21 Courses)

Collapse Shifting the Balance Between the Immune System and Cancer: Moving Beyond the PD-1/PD-L1 Axis

Mechanisms of Immune-Related Adverse Events Expand Mechanisms of Immune-Related Adverse Events for more information

Collapse Mechanisms of Immune-Related Adverse Events

Please note: this course is no longer eligible for continuing education credits.

Published December 24, 2020

Course Description

This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs). The foundational knowledge presented in this course is critical to understanding how and why immune-related adverse events occur and how they can be treated.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Pradnya Patil, MD, FACP

Hematology/Oncology Fellow

Taussig Cancer Institute, Cleveland Clinic

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Discuss the mechanisms of peripheral and central immune tolerance.
Describe the biological pathways involved in mediating autoimmune reactions.
Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: December 24, 2020 - December 24, 2021

Estimated time to complete activity: 0.5 hour

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2520-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Original Course Date: December 24, 2020

Approved Credit:

: 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.50 hours Contact Hour

ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.50 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts Expand Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts for more information

Collapse Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts

Published October 26, 2020

Check out our updated version- Certificate in Cancer Immunotherapy - Module 2 (As of 11/14/2022*), Available now....

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 2: Basic Cancer Immunotherapy Concepts, will cover the biological foundation of cancer immunotherapy, applying the basic immunology you learned in the last module to help lay the foundation for future topics in this program.

Click on image for FREE PREVIEW

Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty
Hussein Tawbi, MD, PhD
Deputy Chair and Professor, Department of Melanoma Medical Oncology
Director of Melanoma Clinical Research & Early Drug Development
Co-Director, MD Anderson Brain Metastasis Clinic
University of Texas MD Anderson Cancer Center, Houston, TX

Learning Objectives

Topic

At the conclusion of this activity, the participant should be able to:

Basis of Tumor Immunosurveillance and Immunotherapy

Describe how the immune system recognizes and eliminates cancer cells, including the concept of immunologic memory.
Characterize the function of specific immune cell populations in mediating tumor immunotherapy and/or immune suppression.
Distinguish between immunosurveillance, immunoediting and immunotherapy of cancer.
Identify the implications of immune depleted, excluded and infiltrated tumor microenvironments.
Identify how both central and peripheral tolerance can impact immunosurveillance and immunotherapy.
Describe the difference between primary and acquired resistance to immunotherapy.
Apply concepts of the cancer-immunity cycle to identify how biomarkers inform and influence tumor immunotherapy.

Immunologic effects of other therapies

Describe the immunologic effects of standard cancer therapeutics on the tumor microenvironment and immune system.
Describe the potential impact of other, non-cancer agents, on tumor immunotherapy responses and toxicities.
Characterize the impact of standard cancer treatments on the efficacy of cancer immunotherapy.
Characterize the impact of standard cancer treatments on the toxicity of cancer immunotherapy.
Distinguish total body versus focal radiotherapy effects.
Recognize the impact of intratumoral injection and other local therapies on the tumor microenvironment and anti-tumor immune response.

SITC Online Education Disclaimer

Continuing Education Information

Date of CE Release: 10/27/22
Date of CE Expiration: 10/27/23
Approximate Time to Complete: 90 minutes

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacist

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

ABIM MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.

FIRST NAME	LAST NAME	RELATIONSHIP:COMMERCIAL INTEREST
Hussein	Tawbi	Genentech, BMS, Novartis, Merck, Array: Consulting Fees Genentech, BMS, Novartis, Merck, GSK: Contracted Research
Silvia	Formenti	Grant/Research support from: Bristol Myers Squibb, Varian, Eli-Lilly, Janssen, Regeneron,Eisai, Merck: Contracted Research Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Accuray: Honoria

Method of Participation and Request for Credit
During the period 10/27/2022 through 10/27/23 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Original Course Date: October 26, 2020

On-Demand Release Date: Available Now

Approved Credit:

: 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 1.50 hours Contact Hour

ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 1.50 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Immunotherapy for the Treatment of Breast & Gynecologic Cancers Expand Immunotherapy for the Treatment of Breast & Gynecologic Cancers for more information

Collapse Immunotherapy for the Treatment of Breast & Gynecologic Cancers

This version of the course is no longer available for credit. To access the accredited version go here to find the Immunotherapy for the Treatment of Breast and Gynecologic Cancers that is a CME-, CPE-, CNE- and MOC-certified activity.

Published August 11, 2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the still emerging applications of Breast and Gynecologic Cancer Immunotherapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for Breast and Gynecologic Cancer.

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty

Evanthia Roussos Torres, MD, PhD
Assistant Professor of Medicine, Oncology
University of Southern California
Norris Comprehensive Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
Implement cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
Describe the rationale for common approaches to cancer immunotherapy

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 8/11/20 - 8/11/21

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.

Joint Accreditation Statement

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2249-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Evanthia Roussos Torres, MD, PhD: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 8/11/20 through 8/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Breast & Gynecologic Cancers.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: August 11, 2020

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Immunotherapy for the Treatment of Microsatellite Instability-High Cancers Expand Immunotherapy for the Treatment of Microsatellite Instability-High Cancers for more information

Collapse Immunotherapy for the Treatment of Microsatellite Instability-High Cancers

Please note, this course is no longer eligible to receive CE credits.

Published July 29,2020

Course Description

This course, Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers, provides background on MSI and an overview of immunotherapy treatment for MSI-high populations. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for MSI-high cancers.

Target Audience

Faculty

John C. Leighton, Jr., MD
Division Chair, Hematology and Medical Oncology
Einstein Healthcare Network

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe microsatellite instability and the implications for immunotherapy treatment
Provide cancer immunotherapy treatment for microsatellite instability – high cancers
Describe the rationale for common approaches to cancer immunotherapy

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 7/29/20 - 7/29/21

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2214-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.2 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

John C. Leighton, Jr., MD: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 7/29/20 through 7/29/21 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: July 29, 2020

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Optimizing Management of Adverse Events Associated with Immunotherapy Expand Optimizing Management of Adverse Events Associated with Immunotherapy for more information

Collapse Optimizing Management of Adverse Events Associated with Immunotherapy

While it is well established that immunotherapies have unique toxicity profiles, effective management is not clearly defined and a challenge for many cancer teams. As evidence emerges on severity and onset of immune-related adverse events (irAEs), it is imperative that clinicians stay abreast of strategies to improve awareness, risk-assessment, monitoring, and management of irAEs including dosing modifications for immunotherapies. Experts will discuss these critical issues as well as the importance of a coordinated approach with multiple specialists for effective irAE management.

This activity is intended for medical, surgical, radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.

Learning Objectives:

Anticipate unique and common immune-related adverse events associated with immunotherapy across a wide range of solid tumors
Implement expert-recommended best practices for managing adverse effects that can occur with immunotherapy

Approximate Time to Complete: 60 minutes

Credit Available: June 10, 2020 - February 28, 2021

Developed through a collaboration between SITC and PlatformQ.

Original Course Date: July 24, 2020

Approved Credit:

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

Life After Immunotherapy: Coordinating Care and Survivorship Plans Expand Life After Immunotherapy: Coordinating Care and Survivorship Plans for more information

Collapse Life After Immunotherapy: Coordinating Care and Survivorship Plans

Effective survivorship care requires coordination among a team of specialists, as well as counseling and education that enables patients to effectively manage their post-treatment health and well-being. As the long-term effects of checkpoint inhibitors are incorporated into survivorship planning, a multidisciplinary panel will discuss evidence-based strategies to provide a framework to address the unique needs of patients treated with immunotherapy.

Learning Objectives:

Apply recent guidelines and expert recommendations for the creation of comprehensive survivorship plans for patients who have received immune checkpoint inhibitors
Plan strategies on developing survivorship plans within your multidisciplinary cancer care team

Approximate Time to Complete: 60 minutes

Credit Available: June 10, 2020 - February 28, 2021

Developed through a collaboration between SITC and PlatformQ.

Original Course Date: July 24, 2020

Approved Credit:

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

Evidence-based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations Expand Evidence-based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations for more information

Collapse Evidence-based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations

Immunotherapy has permeated the cancer treatment landscape among several tumor types and treatment settings. With key late-stage clinical trials underway, immunotherapy experts provide critical updates on emerging data, recent approvals, and promising immunotherapy combinations with other classes of agents. Updates will be provided across solid tumors with opportunities to ask critical clinical questions and receive expert answers.

This activity is intended for medical, surgical, radiation oncologists and other healthcare professionals (i.e. oncology nurses, physicians’ assistants, pharmacists, and others) interested/involved in the care of patients with cancer, who are being treated with immunotherapy.

Learning Objectives:

Examine the relevance of phase II and III trial data regarding emerging indications in solid tumors for immune checkpoint inhibitors
Assess latest clinical trial data on immune checkpoint inhibitors across a wide range of tumors and implement new practice standards accordingly
Recognize the rationale(s) behind combining checkpoint inhibitors with other anti-cancer drugs, including chemotherapy, targeted therapies, and other immunotherapy
Plan to effectively implement evidence-based new approaches of combination regimens with checkpoint inhibitors as they become available

Approximate Time to Complete: 60 minutes

Credit Available: June 10, 2020 - February 28, 2021

Developed through a collaboration between SITC and PlatformQ.

Original Course Date: July 24, 2020

Approved Credit:

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

Immunotherapy for the Treatment of Lung Cancer Expand Immunotherapy for the Treatment of Lung Cancer for more information

This version of the course is no longer available for credit. To access the accredited version, go here to find the Immunotherapy for the Treatment of Lung Cancer that is a CME-, CPE-, CNE-, and MOC-certified activity.

Published July 15, 2020

Course Description

This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals. Learners will have an opportunity to interactively apply what they've learned through an in-depth case study. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.

Target Audience

Faculty

Deepa Rangachari, M.D.
Assistant Professor of Medicine, Harvard Medical School
Thoracic Oncology Program, Beth Israel Deaconess Medical Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Implement cancer immunotherapy treatment for lung cancer.
Identify the appropriate clinical management of common side effects of immunotherapy agents.
Describe the rationale for common approaches to cancer immunotherapy.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: July 15, 2020 - July 15, 2021

Approximate Time to Complete: 60 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2190-H01)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Deepa Rangachari, MD: Contracted research support from Bristol Myers Squibb, Novocure, and Abbvie/Stemcentrx; consulting fees from Astra Zeneca, DynaMed, and Advance Medical/Teladoc Health

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 7/15/20 through 7/15/21 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Lung Cancer.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: July 15, 2020

Approved Credit:

: 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

ANCC: 1 hour Contact Hour

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

ACPE: 1 hour Contact Hour

CoP: 0.00 hours Certificate of Participation

Refining Patient Selection for Biomarker-Directed Immunotherapy Expand Refining Patient Selection for Biomarker-Directed Immunotherapy for more information

Collapse Refining Patient Selection for Biomarker-Directed Immunotherapy

As diagnostic and therapeutic advances intersect, there is a significant impact on oncology patient care and increased the use of molecular testing to guide treatment decision-making. While these practices are evidence-based, complex, and incorporated into clinical guidelines, their adoption is fraught with challenges including the multiple companion diagnostic tests associated with immunotherapies. Ask an expert pathologist and oncologist your burning questions as they discuss their strategies for improving molecular testing, which biomarkers to test for, interpreting molecular test results, and how that translates to selecting immunotherapy for patients with solid tumors.

Learning Objectives:

Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively

Approximate Time to Complete: 60 minutes

Credit Available: June 10, 2020 - February 28, 2021

Developed through a collaboration between SITC and PlatformQ.

Original Course Date: June 10, 2020

Approved Credit:

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

Immunotherapy for the Treatment of Skin Cancers Expand Immunotherapy for the Treatment of Skin Cancers for more information

This course is no longer available for credit.

Published May 26, 2020

Course Description

This course, Immunotherapy for the Treatment of Skin Cancers, provides the latest in immunotherapy treatment for skin cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancers.

Target Audience

Faculty

Ryan J. Sullivan, MD
Assistant Professor of Medicine
Harvard Medical School, Boston, MA
Division of Hematology/Oncology, Department of Medicine
Massachusetts General Hospital, Boston MA

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy.
Implement cancer immunotherapy treatment for skin cancers.
Identify common side effects of immunotherapy agents.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 5/26/20 - 5/26/21

Approximate Time to Complete: 75 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2143-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Ryan J. Sullivan, MD: Consulting Fees (Merck, Novartis, Replimune, Bristol Myers Squibb, Asana Biosciences); Contracted Research (Merck, Amgen)

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Skin Cancers.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: May 26, 2020

Approved Credit:

: 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™

ANCC: 1.30 hours Contact Hour

ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™

ACPE: 1.25 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Immunotherapy for the Treatment of Hepatocellular Carcinoma Expand Immunotherapy for the Treatment of Hepatocellular Carcinoma for more information

Collapse Immunotherapy for the Treatment of Hepatocellular Carcinoma

This course is no longer available for credit.

Originally published May 26, 2020 (Updated June 9. 2020)

Course Description

This course, Immunotherapy for the Treatment of Hepatocellular Carcinoma (HCC), provides an overview of liver immunobiology and immunotherapeutic strategies in HCC, including checkpoint inhibition, blocking inhibitory cytokines, vaccine therapies, oncolytic viruses, and adoptive cell therapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for HCC.

Target Audience

Faculty

Anuradha Krishnamurthy, MD
Assistant Professor of Medicine
University of Pittsburgh School of Medicine

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the characteristics of liver immunobiology
Implement cancer immunotherapy treatment for HCC and better manage common side effects
Describe the rationale for common approaches to cancer immunotherapy

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 5/26/20 - 5/26/21

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2142-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Anuradha Krishnamurthy, MD: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hepatocellular Carcinoma.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: May 26, 2020

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Case Studies in Head and Neck Cancer: What Is the Best Sequence of Therapy? Expand Case Studies in Head and Neck Cancer: What Is the Best Sequence of Therapy? for more information

Collapse Case Studies in Head and Neck Cancer: What Is the Best Sequence of Therapy?

Case Studies in Head and Neck Cancer: What Is the Best Sequence of Therapy The role of immunotherapy in the treatment of patients with advanced squamous cell carcinoma of the head and neck (SCCHN) is explored through two cases.

The cases presented are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice.

This activity is intended for hematologist/oncologists, surgeons, and other healthcare professionals who treat patients with SCCHN.

The goal of this activity is to increase understanding of current approaches to treating advanced SCCHN with immunotherapy.

Learning Objectives:

Have increased knowledge regarding the clinical study designs, as well as efficacy and safety findings, from trials that have evaluated immune checkpoint inhibitor regimens in patients with recurrent or metastatic SCCHN.
Have greater competence related to identifying tumor characteristics and other clinical features that guide treatment selection in patients with recurrent or metastatic SCCHN.
Have greater competence related to strategies for monitoring and managing treatment-related adverse events.

Approximate Time to Complete: 60 minutes

Credit Available: May 15, 2020 - May 15, 2021

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" (Published July 15, 2019)

View On-Demand Webinar Here.

Original Course Date: May 15, 2020

Approved Credit:

: 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm? Expand Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm? for more information

Collapse Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm?

Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm? Experts discuss the current role of checkpoint inhibition in hepatocellular cancer (HCC) as well as the emergence of combination therapies.

The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of HCC.

This activity is intended for hematologists/oncologists, gastroenterologists, nurses/nurse practitioners, pharmacists, and other healthcare professionals who treat patients with advanced hepatocellular cancer.

Learning Objectives:

Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors (ICIs) in managing unresectable HCC.
Have greater competence related to identifying when an ICI should be considered for a patient with unresectable/advanced HCC.
Have greater competence related to managing immune-related adverse events (irAEs) in patients with unresectable HCC.

Approximate Time to Complete: 45 minutes

Credit Available: May 8, 2020 - May 8, 2021

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

Original Course Date: May 08, 2020

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ANCC: 0.75 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours CEU

Immunotherapy for the Treatment of Head and Neck Cancer Expand Immunotherapy for the Treatment of Head and Neck Cancer for more information

Collapse Immunotherapy for the Treatment of Head and Neck Cancer

Originally published April 30, 2020 (updated May 7, 2020)

Course Description

This course, Immunotherapy for the Treatment of Head and Neck Cancer, provides an overview of immunotherapy treatment for head and neck cancer. Multiple clinical trials are discussed, including both mono- and combination therapies. Learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for head and neck cancer.

Target Audience

Faculty

Michael Gibson, MD, PhD FACP
Associate Professor of Medicine
Director of Translational Research for Head and Neck Oncology
Director of Translational Therapeutics for Esophago-Gastric Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe rationale for common approaches to cancer immunotherapy.
Implement cancer immunotherapy treatments for head and neck cancers.
Identify appropriate clinical management of common side effects of immunotherapy agents.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 4/30/20 - 4/30/21

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2066-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Michael Gibson, MD, PhD: Consulting fees to Merck, Bristol-Myers Squibb; Fees for Non-CME/CE services received directly from a commercial interest or their agents to Bristol-Myers Squibb (non-branded)

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 4/30/20 through 4/30/21 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Head and Neck Cancer.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Original Course Date: April 30, 2020

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Test Your Skills: Treating Bladder Cancer Expand Test Your Skills: Treating Bladder Cancer for more information

Collapse Test Your Skills: Treating Bladder Cancer

Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices - order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface.

Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

This activity is intended for Hem/Onc specialists, urologists, and emergency medicine specialists.

The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the diagnosis, evidence-based treatment, counseling, and follow-up related to patients with advanced urothelial cancer.

Learning Objectives:

Have greater competence related to ordering appropriate testing to determine patient eligibility for therapy in advanced urothelial carcinoma (UC).
Have greater competence related to prescribing appropriate therapy in a patient with advanced UC based on patient and disease-specific factors.
Have greater competence related to providing appropriate conseling and follow-up for a patient receiving treatment for advanced UC.

Approximate Time to Complete: 60 minutes

Credit Available: April 28, 2020 - April 28, 2021

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma" (Published August 15, 2017)

Original Course Date: April 28, 2020

Approved Credit:

: 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™

The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial Cancers Expand The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial Cancers for more information

Collapse The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial Cancers

View Available Guidelines Here.

The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial Cancers Read about the latest advances in immuno-and targeted therapies for treating patients with advanced cervical and endometrial cancers.

This activity is intended for hematologist/oncologists, obstetrics/gynecologists, and other healthcare professionals who treat patients with cervical and endometrial cancers.

The goal of this activity is to increase understanding of current standards and new strategies for the treatment of advanced cervical and endometrial cancers.

Learning Objectives:

Have increased knowledge regarding the current standard of care for patients with advanced cervical and endometrial cancers.
Have increased knowledge regarding the clinical trial safety and efficacy data for novel therapies, both alone and in combination with other novel agents, in advanced cervical and endometrial cancers.
Demonstrate greater confidence in their ability to interpret clinical trial data of novel agents in order to understand the impact on the treatment paradigm in advanced cervical and endometrial cancers.

Approximate Time to Complete: 60 minutes

Credit Available: April 10, 2020 - April 10, 2021

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

Original Course Date: April 10, 2020

Approved Credit:

: 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer Expand Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer for more information

Collapse Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer

Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer Experts discuss the use of checkpoint inhibitors in the first and second line for advanced urothelial carcinoma as well as future directions.

This activity is intended for oncologists, urologists, emergency department physicians, and other healthcare professionals who treat patients with bladder cancer.

The goal of this activity is to increase understanding in the latest advances in immunotherapy for the treatment of patients with advanced bladder cancer.

Learning Objectives:

Have increased knowledge regarding the current role for immune checkpoint inhibitors (ICIs) in the treatment of advanced urothelial carcinoma (UC).
Have increased knowledge regarding novel ICIs and novel combination trials in advanced UC.
Have greater competence related to incorporating emerging data into clinical practice when managing patients with advanced UC.

Approximate Time to Complete: 60 minutes

Credit Available: April 8, 2020 - April 8, 2021

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma" (Published August 15, 2017)

Original Course Date: April 08, 2020

Approved Credit:

: 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™

Immunotherapy for the Treatment of Genitourinary Malignancies Expand Immunotherapy for the Treatment of Genitourinary Malignancies for more information

This course is no longer available for credit. Please refer to the newest version of Immunotherapy for the Treatement of Genitourinary Malignancies, published on 11/1/2021.

Originally published March 31, 2020 (updated May 7, 2020)

Course Description

This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for the genitourinary malignancies renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials are discussed, including both mono- and combination therapies. Learners will have an opportunity to interactively apply what they've learned through three case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for genitourinary malignancies.

Target Audience

Faculty

Pedro Barata, MD, MSc
Assistant Professor of Medicine
Deming Department of Medicine
Section of Hematology/Oncology
Tulane University School of Medicine

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe rationale for common approaches to cancer immunotherapy.
Implement cancer immunotherapy treatments for genitourinary malignancies.
Identify appropriate clinical management of common side effects of immunotherapy agents.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 3/31/20 - 3/31/21

Approximate Time to Complete: 1 hour

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2051-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.8 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Pedro Barata, MD, MSc: Consulting Fees (Exelixis, Caris, Bayer, Janssen, EMD-Serono, Pfizer, Astellas, Dendreon, Clovis, Eisai, Sanofi); Contracted Research (BlueEarth Diagnostics, Nektar, AstraZeneca and Seattle Genetics)

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 3/31/20 through 3/31/21 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Genitourinary Malignancies.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: March 31, 2020

Approved Credit:

: 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

ANCC: 1 hour Contact Hour

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

ACPE: 1 hour Contact Hour

CoP: 0.00 hours Certificate of Participation

What's Next for Cancer Immunotherapy? Expand What

This version of the course is no longer available for credit. To access the accredited version, go here to find the What's Next in Cancer Immunotherapy that is a CME-, CPE-, CNE-, and MOC-certified activity.

Published February 11, 2020

Course Description

This course, What's Next for Cancer Immunotherapy?, covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.

Target Audience

Faculty

Evan J. Lipson, MD
Associate Professor, Department of Oncology
Johns Hopkins University School of Medicine

Parul Agarwal, MD
Medical Oncology Fellow
Johns Hopkins University School of Medicine

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale behind expanding the settings in which cancer immunotherapy is administered, including patients with a larger variety of tumor types and patient populations previously excluded from clinical trial participation.
Describe the basis for novel immunotherapy drug combinations.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 2/11/20 - 2/11/21

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-1083-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Evan J. Lipson, MD: Consultant (Bristol-Myers Squibb, Novartis, EMD Serono, Array BioPharma, Macrogenics, Merck); Contracted Research (Bristol-Myers Squibb, Merck)

Parul Agarwal, MD: Nothing to Disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 2/11/20 through 2/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for What's Next for Cancer Immunotherapy?
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: February 11, 2020

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Immunotherapy for the Treatment of Hematologic Malignancies Expand Immunotherapy for the Treatment of Hematologic Malignancies for more information

Please note this course is no longer available for credit. Click here to access the current version of Immunotherapy for the Treatment of Hematologic Malignancies which is a CME-, CPE-, CNE-, and MOC-certified activity.

Originally published January 23, 2020 (Updated May 7, 2020)

Course Description

This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides the latest in immunotherapy treatment for hematological cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for hematologic cancers.

Target Audience

Faculty

Bhagirathbhai R. Dholaria, MBBS
Assistant Professor
Department of Hematology - Oncology
Vanderbilt University School of Medicine, Nashville, TN

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy.
Implement cancer immunotherapy treatment for hematologic cancers.
Identify common side effects of immunotherapy agents.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 1/23/20 - 1/23/21

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-1072-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Bhagirathbhai R. Dholaria, MBBS: Celgene (consulting)

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/23/20 through 1/23/21 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hematologic Malignancies.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: January 23, 2020

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.80 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Toxicity Management Expand Toxicity Management for more information

Published January 16, 2020

Course Description

This course, Toxicity Management, provides an overview of clinical toxicity management for cancer immunotherapy. Both common and uncommon immune-related adverse events (irAEs) are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to manage immune-related adverse events for patients receiving cancer immunotherapy.

Target Audience

Faculty

Morgan Gwynn, PharmD, BCOP, CPP
Melanoma and Head & Neck Oncology Clinical Pharmacist Practitioner
University of North Carolina Medical Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Identify common and uncommon immune-related adverse events associated with cancer immunotherapy
Describe best practices for managing common side effects seen in cancer immunotherapy treatment

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 1/16/20-1/16/21

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-1068-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hour. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Morgan Gwynn, PharmD, BCOP, CPP: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/16/20 through 1/16/21 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Toxicity Management.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: January 16, 2020

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.80 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

2019 Clinician Courses (18 Courses)

Mechanisms of Immune-Related Adverse Events Expand Mechanisms of Immune-Related Adverse Events for more information

This version of the course is no longer available for credit. To access the accredited version go here to find the Mechanisms of Immune-Related Adverse Events that is a CME-, CPE-, CNE- and MOC-certified activity.

Published December 23, 2019

Course Description

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Pradnya Patil, MD, FACP

Hematology/Oncology Fellow

Taussig Cancer Institute, Cleveland Clinic

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Discuss the mechanisms of peripheral and central immune tolerance.
Describe the biological pathways involved in mediating autoimmune reactions.
Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: December 23, 2019 - December 23, 2020

Estimated time to complete activity: 0.5 hour

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-887-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Pradnya Patil, MD, FACP: Nothing to disclose

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 23, 2019 through December 23, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for "Mechanisms of Immune-Related Adverse Events."
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Original Course Date: December 23, 2019

Approved Credit:

: 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.50 hours Contact Hour

ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.50 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Basic Principles of Cancer Immunotherapy Expand Basic Principles of Cancer Immunotherapy for more information

Published December 17, 2019

Course Description

This Basic Principles of Cancer Immunotherapy course covers the basic principles and mechanisms behind cancer immunotherapy.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses, and other healthcare professionals engaged in the care of patients with cancer.

Faculty

Stefani Spranger, PhD
Assistant Professor of Biology
Koch Institute for Integrative Cancer Research at MIT

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy
Recognize various approaches to cancer immunotherapy including therapeutic vaccine, adoptive cell transfer, cytokines, checkpoint inhibitor modulation, effector antibodies and antibody-drug conjugates
Explain the mechanism by which tumors evade the immune system and mechanisms to overcome this immunosuppression
List important biomarkers for measuring the immune response

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 12/17/19-12/17/20

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-991-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.3 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Faculty

Stefani Spranger, PhD: Consulting fees to Venn Therapeutic, Tango, Takeda, Replimune, Ribon, Dragonfly, Merck, Torque; Contracted Research to Takeda, Exelixis

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 12/17/19 through 12/17/20 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Basic Principles of Cancer Immunotherapy.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Firefox, Internet Explorer 7+) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Original Course Date: December 17, 2019

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Practical Barriers in Cancer Immunotherapy Treatment Expand Practical Barriers in Cancer Immunotherapy Treatment for more information

This course is no longer available for credit. Please access the updated course, Practical Barriers in Cancer Immunotherapy Treatment, which is a CME-, CPE-, CNE- and MOC-certified activity.

Published December 10, 2019

Course Description

This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.

At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty

Amy Schippers, PA-C
Physician Assistant
St. Luke's University & Health Network

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting.
Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: 12/10/19-12/10/20

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-983-H04-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour.

Faculty

Amy Schippers, PA-C: Nothing to Disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 12/10/19 through 12/10/20 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for Practical Barriers in Cancer Immunotherapy Treatment.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: December 10, 2019

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Introduction to Immunology - Third Edition Expand Introduction to Immunology - Third Edition for more information

Collapse Introduction to Immunology - Third Edition

This course is no longer available for continuing education credits. Further, this course has been replaced by Module 1 of the SITC Certificate in Cancer Immunotherapy program, Basic Immunology Concepts, as serving as one of the pre-program courses for the ACI Live Virtual events. If you've registered for an ACI Live Virtual event you should have received a coupon code to take Basic Immunology Concepts for free.

Course Description

This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.

introduction_to_Immunology-_third_edition-_thumbnail_image.png

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Christian M. Capitini, MD
Assistant Professor
University of Wisconsin Carbone Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
Differentiate between the adaptive immune system and the innate immune system.
Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: October 9, 2019 - October 9, 2020

Estimated time to complete activity: 1 hour

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-884-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 pharmacotherapy contact hour for Advanced Practice Registered Nurses.

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period October 9, 2019 through October 9, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for "Introduction to Immunology – Third Edition."
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Original Course Date: October 09, 2019

Approved Credit:

: 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

ANCC: 1 hour Contact Hour

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

ACPE: 1 hour Contact Hour

CoP: 0.00 hours Certificate of Participation

2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

Access the updated course, Immunotherapy for the Treatment of Hematologic Malignancies.

Immunotherapy for the Treatment of Hematologic Malignancies, is a CME-, CPE-, CNE- and MOC-certified activity.

Please note that continuing education credit for 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) is only available through May 3, 2019.

Course Description

This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for hematological cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for hematologic cancers and how to identify and manage common side effects of immunotherapy agents.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Naval Daver, MD

Associate Professor

University of Texasw MD Anderson Cancer Center

and

Christian Capitini, MD

Assistant Professor

University of Wisconsin - Madison Carbone Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy.
Implement cancer immunotherapy treatment for hematologic cancers.
Identify the appropriate clinical management of common side effects of immunotherapy agents.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: May 3, 2019 - May 3, 2020

Approximate Time to Complete: 30 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.

Joint Accreditation Statement

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-607-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Christian Capitini, MD - Consulting Fee - Nektar Therapeutics

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 30, 2019 through April 30, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please following the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for 2019 Interactive Course: Hematological Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Original Course Date: May 03, 2019

Approved Credit:

ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.50 hours Contact Hour

ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.50 hours CEU

CoP: 0.00 hours Certificate of Participation

2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)


Access the updated course, Immunotherapy for the Treatment of Skin Cancers. Immunotherapy for the Treatment of Skin Cancers, is a CME-, CPE-, CNE- and MOC-certified activity. Course Description This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for melanoma and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for melanoma and how to identify and manage common side effects of immunotherapy agents. Target Audience This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer. Faculty Isabella Glitza, MD, PhD Oncologist University of Texas MD Anderson Cancer Center Learning Objectives At the conclusion of this activity, the participant should be able to: Describe the rationale for common approaches to cancer immunotherapy. Implement cancer immunotherapy treatment for melanoma. Identify the appropriate clinical management of common side effects of immunotherapy agents. SITC Online Education Disclaimer A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Continuing Education Information Credit Available: May 1, 2019 - May 1, 2020 Approximate Time to Complete: 45 minutes Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer. This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician Continuing Medical Education The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Continuing Pharmacy Education Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-19-606-H01-P) Type of Activity: Knowledge Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses. Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Faculty Isabella Glitza, MD, PhD - Research - Bristol Myers Squib Planners and Managers The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc. Method of Participation and Request for Credit There are no fees for participating and receiving CME credit for this activity. During the period April 24, 2019 through April 24, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. If you wish to receive acknowledgment for completing this activity, please following the steps below: After completing the course, click My Credit from the left-hand side of the SITC connectED homepage. Under Pending Credit, click Request Credit for 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™) Ensure that the appropriate Credit Reporting Organization is selected. Click Continue. Complete the post-test and survey. Click Process Credit. Your Certificate will be available to view in the Submitted Credit section. For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks. Media Internet Hardware and Software Requirements SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Contact PIM: www.pimed.com.
	Original Course Date: May 01, 2019
Approved Credit: ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ ANCC: 0.70 hours Contact Hour ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ ACPE: 0.75 hours Contact Hour CoP: 0.00 hours Certificate of Participation
MORE INFO

Patient-Centered Care in Advanced Bladder Cancer Expand Patient-Centered Care in Advanced Bladder Cancer for more information

Collapse Patient-Centered Care in Advanced Bladder Cancer

Patient-Centered Care in Advanced Bladder Cancer Experts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.

This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with bladder cancer.

The goal of this activity is to discuss the role of immunotherapy, including how to determine eligibility and how to manage immune-related adverse events (irAEs), in the treatment of advanced bladder cancer.

Approximate Time to Complete: 30 minutes

Credit Available: Apr. 30, 2019- Apr. 30, 2020

Developed through a partnership between SITC and Medscape.

Original Course Date: April 30, 2019

Approved Credit:

ABIM: 0.50 hours ABIM MOC Part 2 Credits

ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

The Nurse View: Modulating the Immune System in GI Cancers Expand The Nurse View: Modulating the Immune System in GI Cancers for more information

Collapse The Nurse View: Modulating the Immune System in GI Cancers

The Nurse View: Modulating the Immune System in GI Cancers Nursing experts discuss the emergence of immunotherapy in GI cancers, focusing on the role of biomarkers and the management of irAEs.

This activity is intended for nurses and other healthcare professionals who manage patients with gastrointestinal cancers.

The goal of this activity is to discuss the emerging role of immunotherapy using immune checkpoint inhibitors in patients with gastrointestinal cancers.

Approximate Time to Complete: 30 minutes

Credit Available: Apr. 30, 2019 - Apr. 30, 2020

Developed through a partnership between SITC and Medscape.

Original Course Date: April 30, 2019

Approved Credit:

ANCC: 0.50 hours Contact Hour

2019 Video Series: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Video Series: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Video Series: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Immunotherapy for the Treatment of Head and Neck Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of head and neck cancers. The module also includes case studies on immunotherapy for the treatment of head and neck cancers.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Glenn J. Hanna, MD

Medical Oncologist, Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy in treatment of head and neck cancer patients
Identify the appropriate clinical management of common side effects of immunotherapy agents
Implement cancer immunotherapy treatments for Head and Neck cancers

Continuing Education Information

Approximate Time to Complete: One hour and 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-730-H04-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please following the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for the appropriate course title.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Original Course Date: April 25, 2019

Approved Credit:

ACCME (non-MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 1.70 hours Contact Hour

ACCME (MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 1.75 hours CEU

CoP: 0.00 hours Certificate of Participation

2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

Access the updated course, Immunotherapy for the Treatment of Genitourinary Malignancies

Immunotherapy for the Treatment of Genitourinary Malignancies, is a CME-, CPE-, CNE- and MOC-certified activity.

Course Description

This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for genitourinary cancer, including kidney, bladder and prostate cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for genitourinary cancer (kidney, bladder and prostate cancers), and how to identify and manage common side effects of immunotherapy agents.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Lauren Harshman, MD

Assistant Professor and Co-director, Kidney Cancer Program

Dana-Farber Cancer Institute

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy.
Implement cancer immunotherapy treatment for genitourinary cancers.
Identify the appropriate clinical management of common side effects of immunotherapy agents.

SITC Online Education Disclaimer

Continuing Education Information

Credit Available: March 28, 2019 - March 28, 2020

Approximate Time to Complete: 45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-608-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period March 28, 2019 through March 28, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please following the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Original Course Date: March 28, 2019

Approved Credit:

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours CEU

CoP: 0.00 hours Certificate of Participation

2019 Video Series: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Video Series: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Video Series: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

Course Description

The Immunotherapy for the Treatment of Lung Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of lung cancer. The module also includes case studies on immunotherapy for the treatment of lung cancer.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Deepa Rangachari, MD

Instructor, Medicine, Harvard Medical School

Beth Israel Deaconess Medical Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Discuss the clinical data on the efficacy and mechanism of action of approved therapies
Recognize patient selection criteria for approved therapies
Describe appropriate dosing and sequencing therapies
Identify the appropriate clinical management of common side effects of immunotherapy agents
Implement cancer immunotherapy for the treatment of lung cancers
Describe the rationale for common approaches to cancer immunotherapy in treatment of naive NSCLC patients
Explain the role of biomarkers associated with response or lack of response to immunotherapy including PD-L1, tumor mutational burden (TMB), and epidermal growth factor receptor (EGFR)

Continuing Education Information

Approximate Time to Complete: 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-728-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Deepa Rangachari, MD: No conflict of interest to report.

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please following the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for the appropriate course title.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: January 31, 2019

Approved Credit:

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours CEU

CoP: 0.00 hours Certificate of Participation

2019 Video Series: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Video Series: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Video Series: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)

Course Description

Exemplary video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The Immunotherapy for the Treatment of Melanoma module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of melanoma. The module also includes case studies on immunotherapy for the treatment of melanoma.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Elizabeth Buchbinder, MD

Instructor, Medicine, Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy in treatment of melanoma patients
Identify the appropriate clinical management of common side effects of immunotherapy agents
Implement cancer immunotherapy treatments for melanoma
Describe clinical efficacy of approved immunotherapies
Recognize patient selection criteria for different immunotherapies
Identify factors influencing dosing and choice of immunotherapy relative to other therapies for melanoma

Continuing Education Information

Approximate Time to Complete: 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-729-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.6 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please following the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for the appropriate course title.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patientâ€™s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Original Course Date: January 31, 2019

Approved Credit:

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.60 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours CEU

CoP: 0.00 hours Certificate of Participation

2019 Video Series: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Video Series: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Video Series: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

Course Description

The Immunotherapy for the Treatment of Hematologic Malignancies module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of hematologic malignancies. The module also includes case studies on immunotherapy for the treatment of hematologic malignancies.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Nirav Shah, MD

Assistant Instructor, Medicine

Medical College of Wisconsin

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy for hematologic malignancies
Identify the appropriate clinical management of common side effects of immunotherapy agents
Implement cancer immunotherapy for Hematologic Malignancies
Become familiar with clinical data on the efficacy and mechanism of action of approved therapies
Recognize patient selection criteria for approved therapies
Select appropriate dosing and sequencing of approved therapies

Continuing Education Information

Approximate Time to Complete: One hour and 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-731-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours. Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Nirav Shah, MD: Consulting fees - Juno Therapeutics, Contracted Research - Lentigen Technology, Ownership Interest - Exelexis, Geron, Oncosec

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please following the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for the appropriate course title.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: January 31, 2019

Approved Credit:

ACCME (non-MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 1.70 hours Contact Hour

ACCME (MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 1.75 hours CEU

CoP: 0.00 hours Certificate of Participation

2019 Video Series: Practical Barriers in Cancer Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Video Series: Practical Barriers in Cancer Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Video Series: Practical Barriers in Cancer Immunotherapy (Advances in Cancer Immunotherapy™)

Access the updated course, Practical Barriers in Cancer Immunotherapy Treatment.

Practical Barriers in Cancer Immunotherapy Treatment, is a CME-, CPE-, CNE- and MOC-certified activity.

Please note that continuing education credit for 2019 Video Series: Practical Barriers in Cancer Immunotherapy (Advances in Cancer Immunotherapy^TM) is only available through April 25, 2020.

Course Description

The Practical Barriers in Cancer Immunotherapy module covers practical barriers to implementing immunotherapy in a community setting (operations and reimbursement).. The module also includes a panel discussion in which experts in the field discuss common challenges they have faced including coverage and reimbursement challenges and adverse event managment.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Ryan Weight, DO, MD

Assistant Professor

University of Colorado

Monique Giordana, PharmD, BCOP

Hematology/Oncology Clinical Pharmacy Specialist

Regions Hospital

Lisa A. Kottschade, APRN, MSN, CNP

Associate Professor of Oncology/Nurse Practitioner

Mayo Clinic

Jodi Nordberg

Billing Operations Manager

UM Physicians

Sara Smith, PharmD, BCOP

Oncology Clinical Pharmacist

University of Minnesota Heath Maple Grove

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.

Continuing Education Information

Approximate Time to Complete: One hour and 30 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-733-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Monique Giordana, PharmD, BCOP: No conflict of interest to report.

Lisa Kottschade, APRN, MSN, CNP: Consulting Fees - BMS, Array BioPharma

Jodi Nordberg: Fees for Non-CME/CE Services - Genentech

Sara Smith, PharmD, BCOP: Consulting Fees - Takeda

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for the appropriate course title.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: January 31, 2019

Approved Credit:

ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 1.50 hours Contact Hour

ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 1.50 hours CEU

CoP: 0.00 hours Certificate of Participation

2019 Video Series: Basic Principles of Cancer Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Video Series: Basic Principles of Cancer Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Video Series: Basic Principles of Cancer Immunotherapy (Advances in Cancer Immunotherapy™)

Course Description

The Basic Prinicples of Cancer Immunotherapy module covers the basic principles and mechanisms behind cancer immunotherapy.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Theodore F. Logan, MD

Associate Professor, Medicine

Indiana University Simon Cancer Center

Learning Objectives

At the conclusion of this activy, the participants should be able to:

Describe the rationale for common approaches to cancer immunotherapy
Recognize various approaches to cancer immunotherapy including therapeutic vaccine, adoptive cell transfer, cytokines, checkpoint inhibitor modulation, effector antibodies and antibody-drug conjugates
Explain the mechanism by which tumors evade the immune system and mechanisms to overcome this immunosuppression
List important biomarkers for measuring the immune response

Continuing Education Information

Approximate Time to Complete: 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-727-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.1 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Theodore F. Logan, MD: Consulting - Prometheus Laboratories; Contracted Research - Abbott Laboratories, Abraxix BioSciences, Acceleron Pharma, Amgen, Argos Therapeutics, AstraZeneca, AVEO, BioVex, Breistol-Myers Squibb, Eisai, Lilly, GlaxoSmithKline, Roche, Immatics, Merck, Novartis, Pfizer, Synta, Threshold Pharmaceuticals, Mellennium, TRACON Pharma, Cerulean Pharma, EMD Serono, Prometheus Laboratories, Macrogenics, Peloton Therapeutics, Iovance Biotherapeutics, MedImmune, Dynavax

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please following the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for the appropriate course title.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: January 31, 2019

Approved Credit:

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours CEU

CoP: 0.00 hours Certificate of Participation

2019 Video Series: What's Next for Cancer Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Video Series: What

Course Description

The What's Next for Cancer Immunotherapy module covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Christian Capitini, MD

Assistant Professor, Medicine

University of Wisconsin Carbone Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy.
Become familiar with clinical data on the efficacy and mechanism of action of approved therapies.

Continuing Education Information

Approximate Time to Complete: 30 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-734-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Christian Capitini, MD: Consulting Fees - Nektar Therapeutics

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please following the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for the appropriate course title.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: January 31, 2019

Approved Credit:

ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.50 hours Contact Hour

ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.50 hours CEU

CoP: 0.00 hours Certificate of Participation

Immune-Related Adverse Events in Oncology Patients: Would You Know? Expand Immune-Related Adverse Events in Oncology Patients: Would You Know? for more information

Collapse Immune-Related Adverse Events in Oncology Patients: Would You Know?

Immune-Related Adverse Events in Oncology Patients: Would You Know? Apply best practices to monitoring for, diagnose, and manage potential irAEs in patient with cancer receiving ICIs

This activity is intended for hematology/oncology specialists, emergency medicine physicians, and primary care physicians.

The goal of this activity is to build physician confidence in monitoring for, diagnosing, and managing immune-related adverse events (irAEs) that may occur in patients receiving immune checkpoint inhibitors (ICIs).

Approximate Time to Complete: 1 hour

Credit Available: Jan. 16, 2019 - Jan. 16, 2020

Developed through a partnership between SITC and Medscape.

Original Course Date: January 16, 2019

Approved Credit:

ABIM: 1 hour ABIM MOC Part 2 Credits

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

2019 Video Series: Genitourinary Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) Expand 2019 Video Series: Genitourinary Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) for more information

Collapse 2019 Video Series: Genitourinary Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

Course Description

The Immunotherapy for the Treatment of Genitourinary Malignancies module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of Genitourinary Malignancies. The module also includes case studies on immunotherapy for the treatment of Genitourinary Malignancies.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty

Lenard J. Appleman, MD, PhD

Associate Professor of Medicine

UPMC Hillman Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

Describe the rationale for common approaches to cancer immunotherapy for genitourinary malignancies
Identify the appropriate clinical management of common side effects of immunotherapy agents
Implement cancer immunotherapy for genitourinary malignancies
Become familiar with clincial data on the efficacy of approved therapies
Recognize patient selection criteria for approved therapies
Select appropriate dosing and sequencing of approved therapies (including timing and combination approaches)

Continuing Education Information

Approximate Time to Complete: 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Joint Accreditation Statement

Physician Continuing Medical Education

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-732-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Leonard J. Appleman, MD, PhD: Contracted Research - Astellas, BMS, Bayer, Exolius, Merck, Roche

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 17, 2019 through April 17, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please following the steps below:

After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
Under Pending Credit, click Request Credit for the appropriate course title.
Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
Complete the post-test and survey.
Click Process Credit.
Your Certificate will be available to view in the Submitted Credit section.

Original Course Date: January 31, 2018

Approved Credit:

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.70 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours CEU

CoP: 0.00 hours Certificate of Participation

Certificate in Cancer Immunotherapy Modules (10 Courses)

Certificate in Cancer Immunotherapy

Certificate program for licensed physicians (U.S. licensed MD / DO or global equivalent) and practicing, licensed NPs, PAs, PharmDs (or RPh degree holders involved in direct clinical services), or global equivalent, interested in achieving an identifiable designation (SITC-G; G = graduate) for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. The program is also available to others, but they will not be eligible to earn the certificate.

Certificate in Cancer Immunotherapy- SITC-G

Collapse Certificate in Cancer Immunotherapy- SITC-G

The Society for Immunotherapy of Cancer (SITC) is pleased to offer physicians and qualified healthcare providers the opportunity to earn a Certificate in Cancer Immunotherapy, supporting their knowledge and skills to provide effective and safe care for patients treated with cancer immunotherapy. Learners can expect to develop a comprehensive understanding of cancer immunotherapies, including checkpoint inhibitors, cell therapies and many others, as well as the management of side effects, allowing them to successfully implement immunotherapy in clinical practice.

The Certificate in Cancer Immunotherapy consists of eight learning modules and a final assessment. You will earn SITC Graduate in Cancer Immunotherapy (SITC-G) certificate upon successfully completing all the 8 modules and qualfying in the final assessment. The SITC-G certificate identifies a healthcare provider as completing specialized training in cancer immunotherapy. All modules are approved for CME, CNE, CPE and MOC credits, except where noted.

Certificate- SITC Graduate in Cancer Immunotherapy / SITC-G

Cost of certification

SITC Member Price: $200
Non-Member Price: $250

Target Audiences

The primary target audience for the program is treating physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate will also be available to practicing, licensed NPs, PAs, and PharmDs (or RPh degree holders involved in direct clinical services), or global equivalent. The courses will be available to those who are not practicing clinicians, but they will not be eligible to earn the certificate.

Requirements

The requirements to earn the certificate include:

Must be a treating physician (U.S. licensed MD / DO or global equivalent), or a practicing licensed NP, PA, PharmD or RPh degree holder involved in direct clinical services, or global equivalent
Complete the coursework (all eight modules)
- anticipated to be approximately 1 hour each, for a total of 8 hours
Pass all end-of-module assessments
Successfully complete a comprehensive exam covering all modules

Certificate Term

The certificate term is two years. Then, to earn a current certificate, which allows one to continue to use the SITC-G designation, an individual will need to take and pass updated coursework and assessments. If one misses the deadline for reissuance, he or she will need to retake and pass the full program.

Certificate Program Task Force

Chair

Robert L. Ferris, MD, PhD – University of Pittsburgh Medical Center Hillman Cancer Center

Members

Leisha Emens, MD, PhD – University of Pittsburgh Medical Center Hillman Cancer Center
Umar Farooq, MD – University of Iowa
Silvia Formenti, MD – Weill Cornell Medicine
Sigrun Hallmeyer, MD – Advocate Medical Group
Howard Kaufman, MD, FACS – Ankyra Therapeutics/Massachusetts General Hospital
Jose Lutzky, MD, FACP – University of Miami Sylvester Cancer Center
George Weiner, MD – University of Iowa

Requirements

The requirements to earn the certificate include:
• Complete the coursework (all eight modules)—anticipated to be approximately 1.5 hours each for a total of 12–16 hours
• Successfully complete a comprehensive exam covering all modules

Learner Notification

This program consists of eight modules. Continuing Education credit information for the modules can be found below, and at the module level. Please note, that each module counts for a maximum of 1.50 AMA PRA Category 1 Credits™ for physicians and 1.50 contact hours for nurses and 1.50 knowledge-based contact hours for pharmacists.

CONTINUING EDUCATION (CE) LANGUAGE

Certificate in Cancer Immunotherapy Webseries Online

Physicians / Nurses / Pharmacists

	In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM for physicians and 1.50 contact hours for nurses and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

ABIM MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Original Course Date: December 06, 2022

On-Demand Release Date: Available Now

Approved Credit:

SITC-G: 0.00 hours Certificate of Completion

Assessment of Certificate of Completion

Certificate in Cancer Immunotherapy Module 1: Basic Immunology Concepts

Collapse Assessment of Certificate of Completion


You have completed all your modules for Certificate in Cancer Immunotherapy and now is the time for the final assessment. The final assessment consists of 80 multiple choice questions that test on all 8 modules of content. To pass the final assessment, you must receive a grade of 80% or above. You will have 3 attempts and 65 minutes to complete the test in full. If you do not successfully complete the final assessment in those parameters, SITC will require you to go through the modules of content again - please email education@sitcancer.org to have the content reset for you. You will be presented with statements or questions with multiple options. Please select the appropriate option/ options for the given statement / question. Once done, please click submit. For any questions, please reach out to education@sitcancer.org.
	Original Course Date: November 09, 2022 On-Demand Release Date: Available Now
Approved Credit: CoP: 0.00 hours Certificate of Participation
MORE INFO

Published August 3, 2020

Check out our updated version- Certificate in Cancer Immunotherapy - Module 1 (As of 10/14/2022*), Available now....

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 1: Basic Immunology Concepts, will cover some of the key immunology needed to understand the rest of the certificate program.

Click on image for FREE PREVIEW

Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty
Robert L. Ferris, MD, PhD
Hillman Professor of Oncology
Director, UPMC Hillman Cancer Center
Associate Vice Chancellor for Cancer Research
University of Pittsburgh Medical Center, Pittsburgh, PA

Learning Objectives

Topic	At the conclusion of this activity, the participant should be able to:
Basic Properties of the Immune System	Describe the differences between innate immunity and adaptive immunity. Describe the differences between humoral immunity and cellular immunity. Describe the concept of self/non-self discrimination and immunologic memory.
Cells and Tissues of the Immune System	Distinguish between the basic cell types involved in the immune response and their function, including B cells, T cells, natural killer (NK) cells, monocytes/macrophages and dendritic cells (DC). Describe the architecture and functions of various immunologic tissues including the thymus, spleen, lymph nodes and bone marrow.
Innate Immunity	Describe the key components of innate immunity including pattern recognition receptors and cells of the innate immune system. Describe the function and regulation of innate immunity. Describe how activation of innate immunity influences adaptive immune response. Recognize how host cell death influences innate immunity.
Adaptive Immunity	Describe the components of the adaptive immune system including both humoral and cellular immunity. Describe the function and regulation of adaptive immunity. Define immune tolerance. Describe how immune tolerance impacts adaptive immunity.
Antigen Presentation	Distinguish class I and class II MHC antigen presentation. Describe antigen uptake, processing and presentation. Describe the concept of cross-presentation.
Effector Immune Responses	Identify the cell populations involved in effector immune responses. Describe the different mechanisms of effector functions. Describe how effector functions are regulated.
Inhibitory and Activating Immune Regulation	Describe the functions of major suppressive cell populations (regulatory T cells [Treg], and myeloid derived suppressor cells [MDSC]) Describe immunological synapses. Describe the molecular mechanisms of immune cell activation. Describe the molecular mechanisms of immune cell inhibition. Distinguish between immune cell activation and inhibition of suppression as a pharmacological strategy.
Integration of the Immune Response	Describe how the arms of the immune system interact. List the host factors that influence the immune response. List the environmental factors that influence the immune response.

SITC Online Education Disclaimer

Continuing Education Information

Date of CE Release: August 3, 2020
Date of CE Expiration: August 4, 2023
Approximate Time to Complete: 90 minutes

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts to correctly answer 24 out of 30 questions) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacist

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM for physicians, 1.50 contact hours for nurses, and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

ABIM MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.

FIRST NAME

LAST NAME

RELATIONSHIP:COMMERCIAL INTEREST

Robert

Ferris

Aduro Biotech, Inc; Amgen; Astra-Zeneca/MedImmune; Bain Capital Life Sciences; BMS; EMD Serono; GSK; Iovance Biotherapeutics, Inc; Lilly; MacroGenics, Inc; Merck; Nanobiotix; Numab Therapeutics AG; Oncorus, Inc; Ono Pharmaceutical Co. Ltd; Pfizer; PPD (Benitec, Immunicum); Regeneron Pharmaceuticals, Inc; Tesaro; Torque Therapeutics; TTMS; VentiRx Pharmaceuticals:Consulting Fees

Astra-Zeneca/MedImmune; BMS; Merck; Tesaro; TTMS:Contracted Research

Janssen, Eli Lilly, Scibase, DermTech, BMS, Pfizer:Partner Consulting Fees

Regeneron, Janssen, BMS, Abbvie, Novartis, BI, Castle Biosciences, Eli Lilly: Partner Contracted Research

Method of Participation and Request for Credit
During the period 8/3/20 through 8/4/23 participants must read the learning objectives and faculty disclosures and study the educational activity.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Original Course Date: August 03, 2020

On-Demand Release Date: Available Now

Approved Credit:

: 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 1.50 hours Contact Hour

ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 1.50 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts

Published October 26, 2020

Check out our updated version- Certificate in Cancer Immunotherapy - Module 2 (As of 11/14/2022*), Available now....

Click on image for FREE PREVIEW

Learning Objectives

Topic

At the conclusion of this activity, the participant should be able to:

Basis of Tumor Immunosurveillance and Immunotherapy

Describe how the immune system recognizes and eliminates cancer cells, including the concept of immunologic memory.
Characterize the function of specific immune cell populations in mediating tumor immunotherapy and/or immune suppression.
Distinguish between immunosurveillance, immunoediting and immunotherapy of cancer.
Identify the implications of immune depleted, excluded and infiltrated tumor microenvironments.
Identify how both central and peripheral tolerance can impact immunosurveillance and immunotherapy.
Describe the difference between primary and acquired resistance to immunotherapy.
Apply concepts of the cancer-immunity cycle to identify how biomarkers inform and influence tumor immunotherapy.

Immunologic effects of other therapies

Describe the immunologic effects of standard cancer therapeutics on the tumor microenvironment and immune system.
Describe the potential impact of other, non-cancer agents, on tumor immunotherapy responses and toxicities.
Characterize the impact of standard cancer treatments on the efficacy of cancer immunotherapy.
Characterize the impact of standard cancer treatments on the toxicity of cancer immunotherapy.
Distinguish total body versus focal radiotherapy effects.
Recognize the impact of intratumoral injection and other local therapies on the tumor microenvironment and anti-tumor immune response.

SITC Online Education Disclaimer

FIRST NAME	LAST NAME	RELATIONSHIP:COMMERCIAL INTEREST
Hussein	Tawbi	Genentech, BMS, Novartis, Merck, Array: Consulting Fees Genentech, BMS, Novartis, Merck, GSK: Contracted Research
Silvia	Formenti	Grant/Research support from: Bristol Myers Squibb, Varian, Eli-Lilly, Janssen, Regeneron,Eisai, Merck: Contracted Research Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Accuray: Honoria

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Original Course Date: October 26, 2020

On-Demand Release Date: Available Now

Approved Credit:

: 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 1.50 hours Contact Hour

ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 1.50 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Certificate in Cancer Immunotherapy Module 3: Immune Checkpoint Blockade

Collapse Certificate in Cancer Immunotherapy Module 3: Immune Checkpoint Blockade

Published December 1, 2020

Check out the updated version with new FDA drug approvals (As of 03/20/2023*), Available now......

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 3: Immune Checkpoint Blockade, will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.

Click on image for FREE PREVIEW

Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty
Robert L. Ferris, MD, PhD
Hillman Professor of Oncology
Director, UPMC Hillman Cancer Center
Associate Vice Chancellor for Cancer Research
University of Pittsburgh Medical Center, Pittsburgh, PA

Learning Objectives

Topic	At the conclusion of this activity, the participant should be able to:
Basic Mechanisms of Checkpoint Blockade in Immunotherapy	Describe the basis for co-stimulation in T cell activation and priming. Explain the mechanisms and consequences of co-inhibitory immune checkpoint receptors (ICR). Identify negative downstream regulatory motifs and pathways associated with ICR signaling. Distinguish the distinct activities of antibodies that target PD-1 compared to those that target PD-L1
Biomarkers of Response to ICB and General Clinical Utility	Describe major biomarkers for patient eligibility for the use of immune checkpoint blockade across cancers (PD-L1 expression and extent, IFN signature, CD8 infiltration, Tumor Mutational Burden) and their relative value for prediction of clinical benefit. Distinguish between validated and investigational biomarkers. Describe the use of biomarkers to predict ORR, PFS and OS. Identify patient-specific factors that may predict response (tumor burden, prior chemotherapy exposure, age, gender, site of disease, prior radiotherapy, etc.).
Immune Checkpoint Inhibitors and Combination Approaches	Describe general clinical benefits of ICB with PD-1 or CTLA-4 monotherapy, or ICB combinations (including IO+IO and IO+other cancer therapy combinations). Distinguish the benefits, dose and schedules of combination ICB versus the benefits, dose and schedule of conventional therapies (chemotherapy, radiation therapy and targeted therapies). Identify validated vs investigational ICB combinations, and relevant cancer types.
Monitoring Response to Checkpoint Blockade	Distinguish response criteria in ICB vs standard cancer treatment. Describe kinetics and patterns of response to ICB. Distinguish pseudoprogression from true disease progression. Identify when to suspend or discontinue ICB treatment.

SITC Online Education Disclaimer

Continuing Education Information

Date of CE Release: December 1, 2022
Date of CE Expiration: December 1, 2023
Approximate Time to Complete: 90 minutes

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacist

FIRST NAME

LAST NAME

RELATIONSHIP:COMMERCIAL INTEREST

Robert

Ferris

Janssen, Eli Lilly, Scibase, DermTech, BMS, Pfizer:Partner Consulting Fees

Regeneron, Janssen, BMS, Abbvie, Novartis, BI, Castle Biosciences, Eli Lilly: Partner Contracted Research

Jose

Lutzky

Castle, Kimera Labs, Array, Iovance: Consulting Fees

BMS, Novartis, Iovance, Replimune, Regeneron: Contracted Research

Method of Participation and Request for Credit
During the period 12/1/22 through 12/1/23 participants must read the learning objectives and faculty disclosures and study the educational activity.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Original Course Date: December 01, 2020

On-Demand Release Date: Available Now

Approved Credit:

: 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 1.50 hours Contact Hour

ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 1.50 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Certificate in Cancer Immunotherapy Module 4: Managing Immune Checkpoint Inhibitor Adverse Events

Collapse Certificate in Cancer Immunotherapy Module 4: Managing Immune Checkpoint Inhibitor Adverse Events

Published September 15, 2021

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 4: Managing Immune Checkpoint Inhibitor Adverse Events, will cover the presentations, diagnosis and management of adverse events resulting from immune checkpoint inhibitor treatments.

Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty
Jason Luke, MD, FACP
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Immunology and Immunotherapy Program
University of Pittsburch Medical Center, Pittsburgh, PA

Learning Objectives

Topic	At the conclusion of this activity, the participant should be able to:
Recognition, Frequency and Kinetics of Immune-Related Toxicities	Identify the immune-related toxicities associated with checkpoint inhibition. Classify severity of immune related side effects. Describe the kinetics of immune-related toxicities of immune checkpoint inhibition. Distinguish immune-related side effects from those related to disease progression. Recognize and manage hyperprogression. Manage concurrent multiple adverse events. Manage immunosuppressive medications used to treat adverse events.
Management of Immune-Related Colitis	Describe how to diagnose immune-related colitis. Describe the frequency and time to development of immune-related colitis associated with distinct immunotherapeutic drugs. Manage grade 1/2 colitis and steroid refractory immune-related colitis.
Management of Immune-Related Pneumonitis	Diagnose immune-related pneumonitis. Describe the frequency of immune-related pneumonitis with distinct cancer types. Manage immune-related pneumonitis.
Management of Immune-Related Endocrinopathies	List immune-related endocrinopathies. Recognize and diagnose immune-related endocrinopathies. Treat immune-related endocrinopathies based on the severity of the toxicity. Counsel patients about long term consequences and management of endocrinopathies.
Management of Immune-Related Hepatitis	Recognize and diagnose immune-related hepatitis. Treat immune-related hepatitis based on the severity of the toxicity.
Management of Immune-Related Cutaneous Events	List immune-related cutaneous events. Recognize and diagnose immune-related cutaneous events. Treat immune-related cutaneous events based on the severity of the toxicity.
Management of Other (Rare) Immune-related Adverse Events	List rare immune-related adverse events. Recognize and diagnose rare immune-related adverse events. Treat rare immune-related adverse events based on the severity of the toxicity.
Unique aspects of IO-containing combination therapies	Describe the patterns and severity of adverse events with IO-containing combination therapies relative to the single agents. Distinguish between immune-related and other toxicities in patients receiving IO-containing combination therapies.
Chronic Toxicities Associated with Cancer Immunotherapy	List chronic toxicities of immunotherapy. Describe the time course of chronic toxicities of immunotherapy. Manage the chronic toxicities of immunotherapy.
Management of Non-Immune-Mediated Adverse Events	List non-immune-mediated adverse events. Recognize non-immune-mediated adverse events. Treat non-immune-mediated adverse events.
Management of ICB therapy in the Context of an Adverse Event	Describe when ICB therapy can be continued, reduced or discontinued in the face of toxicity. Describe when ICB therapy can be reinstated following management of toxicity.

SITC Online Education Disclaimer

Continuing Education Information

Date of CE Release: September 15, 2021
Date of CE Expiration: September 15, 2023
Approximate Time to Complete: 60 minutes

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 75% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacist

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits^TM for physicians, 1.00 contact hours for nurses and 1.00 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
UAN: JA4008163-9999-21-175-H04-P / JA4008163-9999-21-175-H04-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

ABIM MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Relationship: Commercial Entity
Michael	Dougan	Consultant: Genentech-Roche, Tillotts Pharma, Partner Therapeutics
Tiffany	Klopp	NA
Lisa	Kottschade	Consultant: BMS
Claire	Leischer	NA
Jason	Luke	Consulting: Fstar, RefleXion, Xilio Abbvie, Alnylam, Bayer, Bristol-Myers Squibb, Checkmate, Crown, Cstone, Eisai, EMD Serono, Flame, Genentech, Gilead, Kadmon, KSQ, Janssen, Immunocore, Inzen, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, TRex, Werewolf, Xencor; Contracted Research: AbbVie, Agios (IIT), Array (IIT), Astellas, Bristol-Myers Squibb (IIT & industry), Corvus, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Numab, Replimmune, Rubius, Spring bank, Synlogic, Takeda, Trishula, Tizona, Xencor
Jose	Lutzky	Consultant: Castle, Kimera Labs,Regeneron, Replimune, Iovance; Contracted Research: BMS, Replimune, Novartis, Regeneron. Immunocore, Iovance
Scott	McGee-Plys	NA
Jill	Wall	NA
Mary Susan	Warsey	NA

Method of Participation and Request for Credit
During the period 9/15/21 through 9/15/23 participants must read the learning objectives and faculty disclosures and study the educational activity.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Original Course Date: November 02, 2020

On-Demand Release Date: Available Now

Approved Credit:

: 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

ANCC: 1 hour Contact Hour

ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

ACPE: 1 hour Contact Hour

CoP: 0.00 hours Certificate of Participation

Certificate in Cancer Immunotherapy Module 5: Other Approaches (Cytokines, Vaccines, and Immune Cell Engagers)

Collapse Certificate in Cancer Immunotherapy Module 5: Other Approaches (Cytokines, Vaccines, and Immune Cell Engagers)

Published July 7, 2021

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 5: Other Approaches (Cytokines, Vaccines, and Immune Cell Engagers), will cover the biological foundation and clinical implementation of cytokines, vaccines and immune cell engagers as immunotherapies for cancer, including adverse event management.

Francesco Marincola, MD

Senior Vice President

Global Head of Cell Therapy Research

Kite, Refuge Biotech

James Gulley, MD, PhD, FACP

Chief of Genitourinary Malignancies Branch

Director, Medical Oncology Service, CCR Office of the Clinical Director

CCR Deputy Director

Center of Cancer Research, National Cancer Institute

Learning Objectives

Topic	At the conclusion of this activity, the participant should be able to:
Basic Mechanisms	Define the types and functions of cytokines and chemokines used in cancer immunotherapy. Distinguish among the various types of cancer vaccines. Describe the different types and functions of tumor antigens used in cancer vaccines. Classify the different delivery platforms for cancer vaccines. Describe how personalized cancer vaccines differ from standard cancer vaccines. Identify different methods and routes of administration of immunotherapy agents. Define the types of immunologic adjuvants and their distinct functions in promoting immune responses. Recognize the role of innate immune activators in promoting tumor immunotherapy. Describe the mechanism of action of immune cell engagers. Compare and contrast immune cell engagers with adoptive cellular therapies. Describe potential mechanisms of relapse following immune cell engager therapies.
Clinical Use and Development	Appreciate the historical data on vaccine and cytokine treatment of malignancy. List current clinical indications for vaccines, cytokines, and immune cell engagers in cancer treatment. Explain how immunologic boosting can enhance anti-tumor immunity with vaccines. Describe the role of immunotherapy and vaccines in cancer prevention. Characterize new and emerging vaccines, cytokines and immune cell engagers under clinical investigation. Describe how cytokine levels may be used as prognostic and predictive biomarkers for cancer immunotherapy.
Combination Approaches	Describe how cytokines, vaccines, and immune cell engagers can be combined with other immunotherapy agents to promote T cell recruitment and anti-tumor immunity. Recognize the role of non-immune agents in promoting tumor immunity in combination with cytokines, vaccines, and immune cell engagers. Define immunogenic cell death (ICD) and describe how combination approaches promote ICD and anti-tumor immunity. Explain the abscopal effect of local therapy. Describe how other agents can enhance immunotherapy.
Patient Selection, Management and Monitoring	Apply criteria for patient selection for IL-2 or interferon therapy. Identify contraindications to treatment with cytokines. Describe methods needed to safely monitor patients on high-dose IL-2 therapy. Describe criteria for patient selection for vaccine treatment. Identify contraindications to treatment with vaccine therapy. Describe patient selection criteria for immune cell engager therapies. Identify contraindications to immune cell engager therapies. Determine duration of treatment and when to assess patients for clinical response.
Management of Adverse Events	Recognize the type and severity of adverse events associated with cytokine, vaccine, and immune cell engager administration. Apply appropriate interventions to ameliorate toxicities associated with cytokines, vaccines, and immune cell engagers. Identify appropriate institutional and provider resources and procedures needed to manage cytokine-related toxicities. Recognize the importance of continuing education for high-dose cytokine delivery teams. Recognize the interactions between cytokines, vaccines, and immune cell engagers with other immunotherapy and non-immunotherapy cancer agents for causing unknown or unexpected adverse events.

SITC Online Education Disclaimer

Certificate in Cancer Immunotherapy Webseries, Module Five

Date of CE Release: July 7, 2021

Date of CE Expiration: July 7, 2023

Approximate Time to Complete: 90 minutes

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 75% or higher and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.

If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacist

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits^TM for physicians, 1.50 contact hours for nurses and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

UAN: JA4008163-9999-21-141-H04-P / JA4008163-9999-21-141-H04-T

ABIM MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1—6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Relationship: Commercial Entity
Aaron	Brodersen	NA
Leisha	Emens	Consultant: Genentech, F Hoffman La Roche, Syndax, Lilly, AbbVie, Amgen, Astrazeneca, Bayer, Bristol Myers Squibb, Celgene, Chugai, Genentech, F Hoffman La Roche, Gritstone, Medimmune, Macrogenics, Novartis, Peregrine, Replimune, Silverback, Vaccinex; Contracted Research: Aduro Biotech, Astrazeneca, Bristol Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La Roche, Maxcyte, Merck, Tempest; Royalties: Elsevier
Umar	Farooq	Consultant: Kite Pharma, Inc
James	Gulley	NA
Tiffany	Klopp	NA
Jane	Kosirog-Glowcki	NA
Claire	Leischer	NA
Francesco	Marincola	Consulting: Calidi Biotechnologie
Scott	McGee-Plys	NA
Edwin	O'Sullivan	Ownership Interest: Aveo Oncology
Emily	Shepard	NA
Jill	Wall	NA

Method of Participation and Request for Credit
During the period 7/1/2021 through 7/1/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Original Course Date: December 07, 2020

On-Demand Release Date: Available Now

Approved Credit:

: 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 1.50 hours Contact Hour

ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 1.50 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Certificate in Cancer Immunotherapy Module 6: Oncolytic Viruses and Local Therapy

Collapse Certificate in Cancer Immunotherapy Module 6: Oncolytic Viruses and Local Therapy

Published 10/11/2021

Check out our updated version- Certificate in Cancer Immunotherapy - Module 6 (As of 11/29/2022*), Available now....

Please note, this activity does not offer continuing education credit.

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 6: Oncolytic Viruses and Local Therapy, will cover the biological foundation and clinical implementation of intratumoral therapies and oncolytic viruses.

Brian Gastman, MD
Professor, Department of Surgery, School of Medicine
Member, Hematopoietic and Immune Cancer Biology Program, Case Comprehensive Cancer Center
Case Western Reserve University, Cleveland, OH
Department of Plastic Surgery
Cleveland Clinic Main Campus, Cleveland, OH

Ann Silk, MD, MS
Co-Director of the Merkel Cell Carcinoma Center of Excellence
Dana-Farber Cancer Institute, Boston, MA

Learning Objectives

Topic	At the conclusion of this activity, the participant should be able to:
Basic Mechanisms of Oncolytic Viruses and Intralesional Therapy	Describe the rationale for intralesional therapy as a strategy for modulating tumor cells and promoting immunity. Distinguish the differences between oncolytic viruses and non-viral intralesional approaches. Classify the different viruses available for cancer immunotherapy and their advantages and disadvantages. List approved oncolytic viruses and intralesional agents. Describe the dual mechanism of action of oncolytic viruses in mediating anti-tumor immunity. Identify how oncolytic viruses can deliver transgenes to promote anti-tumor activity. Describe alternative delivery routes of administration for oncolytic viruses and other intralesional agents.
Patient Selection and Monitoring for Oncolytic Virus Therapies and Intralesional Therapy	Identify eligible patients for oncolytic viruses and intralesional therapy. Determine when oncolytic viruses and/or intralesional therapy should be considered in patient management. Select appropriate tumors for injection of an oncolytic virus and/or intralesional therapy. Determine the volume of oncolytic virus and/or intralesional agent for patient therapy. Describe the process of injecting oncolytic viruses and/or intralesional treatments in patients with cancer. Identify the role of interventional radiology in administration of intralesional treatments to deep and/or visceral tumors. Apply appropriate injection site management following injection of intralesional agents. Define the patterns of response with oncolytic viruses and other intralesional treatments. Identify contraindications to oncolytic virus and/or intralesional therapy. Outline the potential role for oncolytic viruses and intralesional therapy as part of combination regimens for patients with cancer.
Management of Oncolytic Virus and intralesional therapy Adverse Events	Identify the most common adverse events seen with oncolytic viruses and/or other intralesional treatments. Prescribe appropriate intervention for managing common adverse events associated with oncolytic viruses and intralesional therapies.
Logistical and Biosafety Issues Associated with Oncolytic Virus Therapy	Describe the biosafety issues associated with oncolytic virus administration. Recognize the potential for bioshedding and contact transmission associated with oncolytic viruses. Explain how to modify patient flow to optimize integration of oncolytic viruses and intralesional treatments into clinical practice. Implement standard operating procedures for safe delivery of oncolytic viruses and intralesional treatments into clinical practice.

SITC Online Education Disclaimer

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. To earn the SITC-G designation, you must participate in the entire activity.

Method of Participation and Request for Credit
During the period 10/11/2021 through 10/11/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Original Course Date: January 04, 2021

On-Demand Release Date: Available Now

Approved Credit:

CoP: 0.00 hours Certificate of Participation

Certificate in Cancer Immunotherapy Module 7: CAR T Cell and Cellular Therapy

Collapse Certificate in Cancer Immunotherapy Module 7: CAR T Cell and Cellular Therapy

Published 12/1/2021

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 7: CAR T Cell and Cellular Therapy, will cover the mechanisms and clinical administration of cellular therapies for cancer, including an emphasis on adverse event management.

Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty
Carl June, MD
Richard W. Vague Professor In Immunotherapy, Department of Pathology and Laboratory Medicine
Director, Parker Institute for Cancer Immunotherapy
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Learning Objectives

Topic	At the conclusion of this activity, the participant should be able to:
Basic Mechanisms of Adoptive T Cell Immunotherapy	Describe the biologic basis for adoptive T cell therapy of cancer. Define significance of different target antigens and signaling moieties in CAR T cell activity. Contrast the differences between CAR T and other adoptive T cell strategies. Distinguish between different CAR T preparations such as target antigen but also viral vector culture conditions and signaling moieties.
Cellular therapies and Current Clinical Indications	Classify the types of adoptive T cell therapies approved for cancer treatment. Describe clinical indications of approved therapies. Describe off-label uses of CAR T cell therapy.
Patient Selection for T Cell-based Therapy	Identify when patients should be referred for cellular therapy. Recognize contraindications to adoptive cell administration. Describe the timeline of adoptive cellular therapy preparation and administration.
Management of CAR T Cell Administration and Adverse Events	Describe the preparation of CAR T and patient disease management prior to administration. Recognize the different types and patterns of CAR T-related toxicity. Outline approaches to monitoring patients for CAR T-related toxicity including cytokine release syndrome and neurotoxicity. Describe grading and management of cytokine release syndrome and neurotoxicity. Describe typical kinetics of response of malignancy to CAR T cell therapy. Describe long term monitoring and management of CAR T cell patients including identification and management of long term toxicities such as cytopenias and immuno-deficiency. Describe the resources required for outpatient management of CAR T cell therapy
Requirements for CAR T Cell Program Development	Describe the requirements for site certification for administering cellular therapies, including REMS training. Identify other medical specialists who need to participate in REMS training and care of CAR T patients. Outline data reporting requirements for CAR T cell programs. Describe in-patient versus out-patient management and monitoring of CAR T cell patients.

SITC Online Education Disclaimer

Continuing Education Information

Date of CE Release: December 1, 2021
Date of CE Expiration: December 1, 2023
Approximate Time to Complete: 30 minutes

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 75% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacist

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM for physicians, 0.50 contact hour for nurses, and 0.50 knowledge-based contact hour for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

UAN: JA4008163-9999-21-218-H04-P / JA4008163-9999-21-218-H04-T

ABIM MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.

FIRST NAME	LAST NAME	RELATIONSHIP:COMMERCIAL INTEREST
Jennifer	Brudno	NA
Umar	Farooq	Kite Pharma: Consulting
Meredith	Ginn	NA
Carl	June	Novartis: Royalties; AC Immune, Bluesphere Bio, Cellares, Celldex, Cabaletta, Carisma, DeCART, Kiadis, Poseida, Viracta, WIRB-Copernicus Group: Consulting
Huma	Kahn	NA
Tiffany	Klopp	NA
Claire	Leischer	NA
Scott	McGee-Plys	NA
Jill	Wall	NA

Method of Participation and Request for Credit
During the period 12/1/2021 through 12/1/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Original Course Date: February 01, 2021

On-Demand Release Date: Available Now

Approved Credit:

: 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.50 hours Contact Hour

ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.50 hours Contact Hour

CoP: 0.00 hours Certificate of Participation

Certificate in Cancer Immunotherapy Module 8: Implementing Cancer Immunotherapy in Clinical Practice

Collapse Certificate in Cancer Immunotherapy Module 8: Implementing Cancer Immunotherapy in Clinical Practice

Published 5/2/2022

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 8: Implementing Cancer Immunotherapy in Clinical Practice, will cover the practical aspects of instituting immunotherapy treatments in a clinical practice, such as education considerations, value-based care, and access to patient and provider resources.

Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty
Sigrun Hallmeyer, MD
Director, Advocate Medical Group
Member, Division of Hematology/Oncology
Advocate Lutheran General Hospital, Park Ridge, IL

Learning Objectives

Topic	At the conclusion of this activity, the participant should be able to:
How Cancer Immunotherapy Integrates into Value-based Clinical Care	Contrast the role of IO versus standard cancer therapies in the setting of personalized care approaches. Evaluate IO in the NCCN/ASCO value framework. Interpret published data on Patient Reported Outcomes. Analyze cost of IO in the setting of quality of life, earning potential preserved, duration of response, and duration of therapy.
Optimizing Resources for Cancer Immunotherapy Patient Care	Identify and access local, regional and national support foundations and financial support programs. Identify patient education resources. Tailor patient and staff communication to the dynamic and complex nature of IO, including continuous education strategies, telemedicine, etc.
Educating Non-cancer Professionals about Cancer Immunotherapy	Build a dedicated multidisciplinary team with expertise in immuno-oncology administration, adverse events diagnosis and management. Develop subspecialty-targeted learning programs for education on IO. Identify best practices of communicating with primary care physicians and emergency physician on how to recognize treatment related adverse events.
Patient Selection in Immunotherapy	Interpret the value and limitations of current biomarkers in different IO settings. Distinguish the risk/benefit ratios for each individual case based on published data, expert opinion or personal experience. Describe the key elements of a detailed informed consent discussion. Describe IO therapy in populations traditionally deemed ineligible for clinical trials

SITC Online Education Disclaimer

Continuing Education Information

Date of CE Release: May 2, 2022
Date of CE Expiration: May 2, 2024
Approximate Time to Complete: 60 minutes

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement

Physicians (ACCME) Credit Designation Amedco LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 0.75 ANCC contact hours.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 0.75 knowledge-based CPE contact hours.

UAN: JA4008163-9999-21-250-H04-P / JA40081863-21-250-H04-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

ABIM MOC CreditSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.

First Name	Last Name	Commercial Interest: Relationship
Robert	Ferris	Achilles Therapeutics, Aduro Biotech, Inc., Bicara Therapeutics, BMS, Brooklyn Immunotherapeutic, Everest Clinical Research Corporation, F. Hoffman-La Roche Ltd, Genocea Biosciences, Inc., Hookipa Biotech GmbH, Instill Bio, Inc., Kowa Research Institute, Inc., Lifescience Dynamics Limited, MacroGenics, Inc., Merck, Mirati Therapeutics, Inc., Nanobiotix, Novasenta, Numab Therapeutics AG, OncoCyte Corporation, Pfizer, PPD Development, L.P., Rakuten Medical, Inc., Sanofi, Seagen, Inc., Vir Biotechnology, Inc., Zymeworks, Inc.: Consulting; Astra-Zeneca/MedImmune, BMS, Merck, Novasenta, Tesaro: Contracted Research; Novasenta: Stock Holder
Robyn	Fine	NA
Bo	Gamble	NA
Sigrun	Hallmeyer	Bristol Myers Squibb (BMS), Cardinal Health: Consulting, Bristol Myers Squibb (BMS): Speaker, Executive Committee ACCC Immuno Oncology Institute: Chair
Tiffany	Klopp	NA
Claire	Leischer	NA
Jo	Shultz	NA
Jill	Wall	NA

Method of Participation and Request for Credit

During the period 5/2/2022 through 5/2/2024 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 75% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Original Course Date: March 01, 2021

On-Demand Release Date: Available Now

Approved Credit:

: 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ANCC: 0.75 hours Contact Hour

ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™

ACPE: 0.75 hours Contact Hour

CoP: 0.00 hours Certificate of Participation